| Year |
Citation |
Score |
| 2024 |
Mohanty V, Baran N, Huang Y, Ramage CL, Cooper LM, He S, Iqbal R, Daher M, Tyner JW, Mills GB, Konopleva M, Chen K. Transcriptional and phenotypic heterogeneity underpinning venetoclax resistance in AML. Biorxiv : the Preprint Server For Biology. PMID 38352538 DOI: 10.1101/2024.01.27.577579 |
0.356 |
|
| 2023 |
Saridogan T, Akcakanat A, Zhao M, Evans KW, Yuca E, Scott S, Kirby BP, Zheng X, Ha MJ, Chen H, Ng PKS, DiPeri TP, Mills GB, Rodon Ahnert J, Damodaran S, et al. Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer. Scientific Reports. 13: 20223. PMID 37980453 DOI: 10.1038/s41598-023-46586-y |
0.445 |
|
| 2023 |
Kinose Y, Xu H, Kim H, Kumar S, Shan X, George E, Wang X, Medvedev S, Ferman B, Gitto SB, Whicker M, D'Andrea K, Wubbenhorst B, Hallberg D, O'Connor M, ... ... Mills GB, et al. Dual blockade of BRD4 and ATR/WEE1 pathways exploits loss in clear cell ovarian cancer. Research Square. PMID 37841875 DOI: 10.21203/rs.3.rs-3314138/v1 |
0.31 |
|
| 2023 |
Doha ZO, Wang X, Calistri NL, Eng J, Daniel CJ, Ternes L, Kim EN, Pelz C, Munks M, Betts C, Kwon S, Bucher E, Li X, Waugh T, Tatarova Z, ... ... Mills G, et al. MYC Deregulation and PTEN Loss Model Tumor and Stromal Heterogeneity of Aggressive Triple-Negative Breast Cancer. Nature Communications. 14: 5665. PMID 37704631 DOI: 10.1038/s41467-023-40841-6 |
0.352 |
|
| 2023 |
Park SY, Jeong KJ, Poire A, Zhang D, Tsang YH, Blucher AS, Mills GB. Irreversible HER2 inhibitors overcome resistance to the RSL3 ferroptosis inducer in non-HER2 amplified luminal breast cancer. Cell Death & Disease. 14: 532. PMID 37596261 DOI: 10.1038/s41419-023-06042-1 |
0.423 |
|
| 2023 |
Lenz L, Neff C, Solimeno C, Cogan ES, Abramson VG, Boughey JC, Falkson C, Goetz MP, Ford JM, Gradishar WJ, Jankowitz RC, Kaklamani VG, Marcom PK, Richardson AL, Storniolo AM, ... ... Mills GB, et al. Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes. Breast Cancer Research and Treatment. PMID 37589839 DOI: 10.1007/s10549-023-07046-3 |
0.327 |
|
| 2023 |
Lei JT, Jaehnig EJ, Smith H, Holt MV, Li X, Anurag M, Ellis MJ, Mills GB, Zhang B, Labrie M. The Breast Cancer Proteome and Precision Oncology. Cold Spring Harbor Perspectives in Medicine. PMID 37137501 DOI: 10.1101/cshperspect.a041323 |
0.384 |
|
| 2023 |
Park KC, Kim JM, Kim SY, Kim SM, Lim JH, Kim MK, Fang S, Kim Y, Mills GB, Noh SH, Cheong JH. PMCA inhibition reverses drug resistance in clinically refractory cancer patient-derived models. Bmc Medicine. 21: 38. PMID 36726166 DOI: 10.1186/s12916-023-02727-8 |
0.345 |
|
| 2023 |
Tatarova Z, Blumberg DC, Bensen A, Mills GB, Jonas O. Panobinostat Induced Spatial In Situ Biomarkers Predictive of Anti-PD-1 Efficacy in Mouse Mammary Carcinoma. Cells. 12. PMID 36672243 DOI: 10.3390/cells12020308 |
0.379 |
|
| 2022 |
Yan G, Luna A, Wang H, Bozorgui B, Li X, Sanchez M, Dereli Z, Kahraman N, Kara G, Chen X, Zheng C, McGrail D, Sahni N, Lu Y, Babur O, ... ... Mills GB, et al. BET inhibition induces vulnerability to MCL1 targeting through upregulation of fatty acid synthesis pathway in breast cancer. Cell Reports. 40: 111304. PMID 36103824 DOI: 10.1016/j.celrep.2022.111304 |
0.47 |
|
| 2022 |
Serra V, Wang AT, Castroviejo-Bermejo M, Polanska UM, Palafox M, Herencia-Ropero A, Jones GN, Lai Z, Armenia J, Michopoulos F, Llop-Guevara A, Brough R, Gulati A, Pettitt SJ, Bulusu KC, ... ... Mills GB, et al. Identification of a molecularly-defined subset of breast and ovarian cancer models that respond to WEE1 or ATR inhibition, overcoming PARP inhibitor resistance. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 35921524 DOI: 10.1158/1078-0432.CCR-22-0568 |
0.394 |
|
| 2022 |
Tatarova Z, Blumberg DC, Korkola JE, Heiser LM, Muschler JL, Schedin PJ, Ahn SW, Mills GB, Coussens LM, Jonas O, Gray JW. A multiplex implantable microdevice assay identifies synergistic combinations of cancer immunotherapies and conventional drugs. Nature Biotechnology. PMID 35788566 DOI: 10.1038/s41587-022-01379-y |
0.406 |
|
| 2022 |
Xiao R, You L, Zhang L, Guo X, Guo E, Zhao F, Yang B, Li X, Fu Y, Lu F, Wang Z, Liu C, Peng W, Li W, Yang X, ... ... Mills GB, et al. Inhibiting the IRE1α Axis of the Unfolded Protein Response Enhances the Antitumor Effect of AZD1775 in TP53 Mutant Ovarian Cancer. Advanced Science (Weinheim, Baden-Wurttemberg, Germany). e2105469. PMID 35619328 DOI: 10.1002/advs.202105469 |
0.376 |
|
| 2022 |
Curtiss BM, VanCampen J, Macaraeg J, Kong GL, Taherinasab A, Tsuchiya M, Yashar WM, Tsang YH, Horton W, Coleman DJ, Estabrook J, Lusardi TA, Mills GB, Druker BJ, Maxson JE, et al. PU.1 and MYC transcriptional network defines synergistic drug responses to KIT and LSD1 inhibition in acute myeloid leukemia. Leukemia. PMID 35590033 DOI: 10.1038/s41375-022-01594-1 |
0.356 |
|
| 2022 |
Liu X, Ge Z, Yang F, Contreras A, Lee S, White JB, Lu Y, Labrie M, Arun BK, Moulder SL, Mills GB, Piwnica-Worms H, Litton JK, Chang JT. Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers. Npj Breast Cancer. 8: 64. PMID 35538088 DOI: 10.1038/s41523-022-00427-9 |
0.411 |
|
| 2022 |
Cathcart AM, Smith H, Labrie M, Mills GB. Characterization of anticancer drug resistance by reverse-phase protein array: new targets and strategies. Expert Review of Proteomics. 1-15. PMID 35466854 DOI: 10.1080/14789450.2022.2070065 |
0.343 |
|
| 2022 |
Johnson BE, Creason AL, Stommel JM, Keck JM, Parmar S, Betts CB, Blucher A, Boniface C, Bucher E, Burlingame E, Camp T, Chin K, Eng J, Estabrook J, Feiler HS, ... ... Mills GB, et al. An omic and multidimensional spatial atlas from serial biopsies of an evolving metastatic breast cancer. Cell Reports. Medicine. 3: 100525. PMID 35243422 DOI: 10.1016/j.xcrm.2022.100525 |
0.369 |
|
| 2021 |
Labrie M, Li A, Creason A, Betts C, Keck J, Johnson B, Sivagnanam S, Boniface C, Ma H, Blucher A, Chang YH, Chin K, Vuky J, Guimaraes AR, Downey M, ... ... Mills GB, et al. Multiomics analysis of serial PARP inhibitor treated metastatic TNBC inform on rational combination therapies. Npj Precision Oncology. 5: 92. PMID 34667258 DOI: 10.1038/s41698-021-00232-w |
0.386 |
|
| 2021 |
Castellanet O, Ahmad F, Vinik Y, Mills GB, Habermann B, Borg JP, Lev S, Lamballe F, Maina F. BCL-XL blockage in TNBC models confers vulnerability to inhibition of specific cell cycle regulators. Theranostics. 11: 9180-9197. PMID 34646365 DOI: 10.7150/thno.60503 |
0.705 |
|
| 2021 |
Xu H, George E, Kinose Y, Kim H, Shah JB, Peake JD, Ferman B, Medvedev S, Murtha T, Barger CJ, Devins KM, D'Andrea K, Wubbenhorst B, Schwartz LE, Hwang WT, ... Mills GB, et al. copy number is a biomarker for response to combination WEE1-ATR inhibition in ovarian and endometrial cancer models. Cell Reports. Medicine. 2: 100394. PMID 34622231 DOI: 10.1016/j.xcrm.2021.100394 |
0.313 |
|
| 2021 |
de Oliveira ÉA, Chauhan J, da Silva JR, da Costa Carvalho LA, Dias D, de Carvalho DG, Watanabe LRM, Rebecca VW, Mills G, Lu Y, da Silva ASF, Consolaro MEL, Herlyn M, Possik PA, Goding CR, et al. TOP1 modulation during melanoma progression and in adaptative resistance to BRAF and MEK inhibitors. Pharmacological Research. 105911. PMID 34560251 DOI: 10.1016/j.phrs.2021.105911 |
0.339 |
|
| 2021 |
Bouhaddou M, Lee RH, Li H, Bhola NE, O'Keefe RA, Naser M, Zhu TR, Nwachuku K, Duvvuri U, Olshen AB, Roy R, Hechmer A, Bolen J, Keysar SB, Jimeno A, ... Mills GB, et al. Caveolin-1 and Sox-2 are predictive biomarkers of cetuximab response in head and neck cancer. Jci Insight. PMID 34546978 DOI: 10.1172/jci.insight.151982 |
0.316 |
|
| 2021 |
Westin SN, Labrie M, Litton JK, Blucher A, Fang Y, Vellano CP, Marszalek JR, Feng N, Ma X, Creason A, Fellman B, Yuan Y, Lee S, Kim T, Liu J, ... ... Mills GB, et al. Phase 1b dose expansion and translational analyses of olaparib in combination with capivasertib in recurrent endometrial, triple negative breast, and ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 34518313 DOI: 10.1158/1078-0432.CCR-21-1656 |
0.318 |
|
| 2021 |
Liu J, Rebecca VW, Kossenkov AV, Connelly T, Liu Q, Gutierrez A, Xiao M, Li L, Zhang G, Samarkina A, Zayasbazan D, Zhang J, Cheng C, Wei Z, Alicea GM, ... ... Mills GB, et al. Neural crest-like stem cell transcriptome analysis identifies LPAR1 in melanoma progression and therapy resistance. Cancer Research. PMID 34462276 DOI: 10.1158/0008-5472.CAN-20-1496 |
0.355 |
|
| 2021 |
Mohanty V, Wang F, Mills GB, Chen K. Uncoupling of gene expression from copy number presents therapeutic opportunities in aneuploid cancers. Cell Reports. Medicine. 2: 100349. PMID 34337565 DOI: 10.1016/j.xcrm.2021.100349 |
0.368 |
|
| 2021 |
Wang B, Zhang W, Zhang G, Kwong L, Lu H, Tan J, Sadek N, Xiao M, Zhang J, Labrie M, Randell S, Beroard A, Sugarman E, Rebecca VW, Wei Z, ... ... Mills GB, et al. Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma. Oncogene. PMID 34304249 DOI: 10.1038/s41388-021-01911-5 |
0.352 |
|
| 2021 |
Parmar S, Keck JM, Kong B, Look R, Johnson B, Patterson J, Labrie M, Guimaraes AR, Corless CL, Beadling C, Kolodzie A, Bergan R, Gray JW, Mills GB, Mitri ZI. Exceptional Response to Trastuzumab in a Heavily Pretreated Patient With ERBB3-Mutated Metastatic Breast Cancer. Jco Precision Oncology. 5. PMID 34250408 DOI: 10.1200/PO.20.00183 |
0.321 |
|
| 2021 |
Dietz MS, Sutton TL, Walker BS, Gast CE, Zarour L, Sengupta SK, Swain JR, Eng J, Parappilly M, Limbach K, Sattler A, Burlingame E, Chin Y, Gower A, Mira JLM, ... ... Mills GB, et al. Relevance of circulating hybrid cells as a non-invasive biomarker for myriad solid tumors. Scientific Reports. 11: 13630. PMID 34211050 DOI: 10.1038/s41598-021-93053-7 |
0.34 |
|
| 2021 |
Haugen MH, Lingjærde OC, Hedenfalk I, Garred Ø, Borgen E, Loman N, Hatschek T, Børresen-Dale AL, Naume B, Mills GB, Mælandsmo GM, Engebraaten O. Protein Signature Predicts Response to Neoadjuvant Treatment With Chemotherapy and Bevacizumab in HER2-Negative Breast Cancers. Jco Precision Oncology. 5. PMID 34036235 DOI: 10.1200/PO.20.00086 |
0.344 |
|
| 2021 |
Blucher AS, Mills GB, Tsang YH. Precision oncology for breast cancer through clinical trials. Clinical & Experimental Metastasis. PMID 33950412 DOI: 10.1007/s10585-021-10092-0 |
0.347 |
|
| 2021 |
Georgopoulou D, Callari M, Rueda OM, Shea A, Martin A, Giovannetti A, Qosaj F, Dariush A, Chin SF, Carnevalli LS, Provenzano E, Greenwood W, Lerda G, Esmaeilishirazifard E, O'Reilly M, ... ... Mills GB, et al. Landscapes of cellular phenotypic diversity in breast cancer xenografts and their impact on drug response. Nature Communications. 12: 1998. PMID 33790302 DOI: 10.1038/s41467-021-22303-z |
0.386 |
|
| 2021 |
Akcakanat A, Zheng X, Cruz Pico CX, Kim T, Chen K, Korkut A, Sahin AA, Holla VR, Tarco E, Singh G, Damodaran S, Mills GB, Gonzalez-Angulo AM, Meric-Bernstam F. Genomic, Transcriptomic and Proteomic Profiling of Metastatic Breast Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33782032 DOI: 10.1158/1078-0432.CCR-20-4048 |
0.329 |
|
| 2021 |
Li A, Keck JM, Parmar S, Patterson J, Labrie M, Creason AL, Johnson BE, Downey M, Thomas G, Beadling C, Heiser LM, Kolodzie A, Guimaraes AR, Corless CL, Gray JW, ... Mills GB, et al. Characterizing advanced breast cancer heterogeneity and treatment resistance through serial biopsies and comprehensive analytics. Npj Precision Oncology. 5: 28. PMID 33772089 DOI: 10.1038/s41698-021-00165-4 |
0.336 |
|
| 2021 |
Lamballe F, Ahmad F, Vinik Y, Castellanet O, Daian F, Müller AK, Köhler UA, Bailly AL, Josselin E, Castellano R, Cayrou C, Charafe-Jauffret E, Mills GB, Géli V, Borg JP, et al. Modeling Heterogeneity of Triple-Negative Breast Cancer Uncovers a Novel Combinatorial Treatment Overcoming Primary Drug Resistance. Advanced Science (Weinheim, Baden-Wurttemberg, Germany). 8: 2003049. PMID 33552868 DOI: 10.1002/advs.202003049 |
0.701 |
|
| 2020 |
Gu G, Tian L, Herzog SK, Rechoum Y, Gelsomino L, Gao M, Du L, Kim JA, Dustin D, Lo HC, Beyer AR, Edwards DG, Gonzalez T, Tsimelzon A, Huang HJ, ... ... Mills GB, et al. Hormonal modulation of ESR1 mutant metastasis. Oncogene. PMID 33323970 DOI: 10.1038/s41388-020-01563-x |
0.362 |
|
| 2020 |
Garrido-Castro AC, Saura C, Barroso-Sousa R, Guo H, Ciruelos E, Bermejo B, Gavilá J, Serra V, Prat A, Paré L, Céliz P, Villagrasa P, Li Y, Savoie J, Xu Z, ... ... Mills GB, et al. Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer. Breast Cancer Research : Bcr. 22: 120. PMID 33138866 DOI: 10.1186/s13058-020-01354-y |
0.338 |
|
| 2020 |
Parashar D, Nair B, Geethadevi A, George J, Nair A, Tsaih SW, Kadamberi IP, Gopinadhan Nair GK, Lu Y, Ramchandran R, Uyar DS, Rader JS, Ram PT, Mills GB, Pradeep S, et al. Peritoneal Spread of Ovarian Cancer harbors Therapeutic Vulnerabilities Regulated by FOXM1 and EGFR/ERBB2 Signaling. Cancer Research. PMID 33087324 DOI: 10.1158/0008-5472.CAN-19-3717 |
0.358 |
|
| 2020 |
Vinik Y, Ortega FG, Mills GB, Lu Y, Jurkowicz M, Halperin S, Aharoni M, Gutman M, Lev S. Proteomic analysis of circulating extracellular vesicles identifies potential markers of breast cancer progression, recurrence, and response. Science Advances. 6. PMID 33008904 DOI: 10.1126/sciadv.aba5714 |
0.647 |
|
| 2020 |
Verma N, Vinik Y, Saroha A, Nair NU, Ruppin E, Mills G, Karn T, Dubey V, Khera L, Raj H, Maina F, Lev S. Synthetic lethal combination targeting BET uncovered intrinsic susceptibility of TNBC to ferroptosis. Science Advances. 6. PMID 32937365 DOI: 10.1126/Sciadv.Aba8968 |
0.691 |
|
| 2020 |
Tsang YH, Mills GB. The roles of variants in pancreatic cancer development and their potential impact on cancer immunotherapy. Autophagy. 1-2. PMID 32809888 DOI: 10.1080/15548627.2020.1802091 |
0.335 |
|
| 2020 |
Kim SJ, Ju JS, Kang MH, Eun JW, Kim YH, Raninga PV, Khanna KK, Győrffy B, Pack CG, Han HD, Lee HJ, Gong G, Shin Y, Mills GB, Eyun SI, et al. RNA-binding protein NONO contributes to cancer cell growth and confers drug resistance as a theranostic target in TNBC. Theranostics. 10: 7974-7992. PMID 32724453 DOI: 10.7150/Thno.45037 |
0.435 |
|
| 2020 |
Zervantonakis IK, Poskus MD, Scott AL, Selfors LM, Lin JR, Dillon DA, Pathania S, Sorger PK, Mills GB, Brugge JS. Fibroblast-tumor cell signaling limits HER2 kinase therapy response via activation of MTOR and antiapoptotic pathways. Proceedings of the National Academy of Sciences of the United States of America. PMID 32601199 DOI: 10.1073/Pnas.2000648117 |
0.436 |
|
| 2020 |
Rao L, Mak VCY, Zhou Y, Zhang D, Li X, Fung CCY, Sharma R, Gu C, Lu Y, Tipoe GL, Cheung ANY, Mills GB, Cheung LWT. p85β regulates autophagic degradation of AXL to activate oncogenic signaling. Nature Communications. 11: 2291. PMID 32385243 DOI: 10.1038/s41467-020-16061-7 |
0.335 |
|
| 2020 |
Blucher AS, Mills GB, Tsang YH. Which path to follow? Utilizing proteomics to improve therapy choices for breast cancer patients. Expert Review of Proteomics. 1-4. PMID 32306787 DOI: 10.1080/14789450.2020.1757442 |
0.306 |
|
| 2020 |
Tsang YH, Wang Y, Kong K, Grzeskowiak C, Zagorodna O, Dogruluk T, Lu H, Villafane N, Bhavana VH, Moreno D, Elsea SH, Liang H, Mills GB, Scott KL. Differential expression of MAGEA6 toggles autophagy to promote pancreatic cancer progression. Elife. 9. PMID 32270762 DOI: 10.7554/Elife.48963 |
0.352 |
|
| 2020 |
Gris-Oliver A, Palafox M, Monserrat L, Brasó-Maristany F, Òdena A, Sánchez-Guixé M, Ibrahim YH, Villacampa G, Grueso J, Parés M, Guzman M, Rodriguez O, Bruna A, Hirst CS, Barnicle A, ... ... Mills GB, et al. Genetic alterations in the PI3K/AKT pathway and baseline AKT activity define AKT inhibitor sensitivity in breast cancer patient-derived xenografts. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32220884 DOI: 10.1158/1078-0432.Ccr-19-3324 |
0.395 |
|
| 2020 |
Lee EK, Tan-Wasielewski Z, Aghajanian C, Coleman RL, Curtis J, Hirsch MS, Matulonis UA, Cantley LC, Mills GB, Doyle LA, Liu JF. Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035). Gynecologic Oncology Reports. 32: 100546. PMID 32083163 DOI: 10.1016/J.Gore.2020.100546 |
0.322 |
|
| 2020 |
Verma N, Müller AK, Kothari C, Panayotopoulou E, Kedan A, Selitrennik M, Mills GB, Nguyen LK, Shin S, Karn T, Holtrich U, Lev S. Correction: Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4-NDRG1 Axis. Cancer Research. 80: 362. PMID 31941679 DOI: 10.1158/0008-5472.CAN-19-3573 |
0.669 |
|
| 2020 |
Lee J, Labrie M, Yong G, Camp T, Ma H, Grout M, Xu W, Beasley G, Schuchter LM, McGettigan S, O'Rourke DM, Herlyn M, Corless CL, Mills GB, Zhang G. Multiomics profiling of longitudinal melanoma specimens unravels molecular mechanisms of resistance to sequential targeted and cancer immunotherapies. Journal of Clinical Oncology. 38: e22015-e22015. DOI: 10.1200/Jco.2020.38.15_Suppl.E22015 |
0.327 |
|
| 2020 |
Sahni N, McGrail DJ, Garnett J, Yin J, Dai H, Shih DJH, Peng G, Menter D, Yates MS, Kopetz S, Lu K, Broaddus R, Mills GB, Lin SY. Abstract NG14: Proteome instability is an immunogenic therapeutic vulnerability in mismatch repair deficient cancer Cancer Research. 80. DOI: 10.1158/1538-7445.Am2020-Ng14 |
0.356 |
|
| 2020 |
Wicker CA, Hunt BG, Palackdharry S, Elaban WR, Mills GB, Wise-Draper T, Waltz S, Takiar V. Abstract 6278: Glutaminase inhibition in combination with ionizing radiation improves treatment response in head and neck squamous cell carcinoma models Cancer Research. 80: 6278-6278. DOI: 10.1158/1538-7445.Am2020-6278 |
0.312 |
|
| 2019 |
Ye Y, Hu Q, Chen H, Liang K, Yuan Y, Xiang Y, Ruan H, Zhang Z, Song A, Zhang H, Liu L, Diao L, Lou Y, Zhou B, Wang L, ... ... Mills GB, et al. Characterization of Hypoxia-associated Molecular Features to Aid Hypoxia-Targeted Therapy. Nature Metabolism. 1: 431-444. PMID 31984309 DOI: 10.1038/s42255-019-0045-8 |
0.328 |
|
| 2019 |
Parashar D, Geethadevi A, Aure MR, Mishra J, George J, Chen C, Mishra MK, Tahiri A, Zhao W, Nair B, Lu Y, Mangala LS, Rodriguez-Aguayo C, Lopez-Berestein G, Camara AKS, ... ... Mills GB, et al. miRNA551b-3p Activates an Oncostatin Signaling Module for the Progression of Triple-Negative Breast Cancer. Cell Reports. 29: 4389-4406.e10. PMID 31875548 DOI: 10.1016/J.Celrep.2019.11.085 |
0.357 |
|
| 2019 |
Labrie M, Fang Y, Kendsersky ND, Li J, Liang H, Westin SN, Mitri Z, Mills GB. Using Reverse Phase Protein Array (RPPA) to Identify and Target Adaptive Resistance. Advances in Experimental Medicine and Biology. 1188: 251-266. PMID 31820393 DOI: 10.1007/978-981-32-9755-5_14 |
0.351 |
|
| 2019 |
Sun C, Li X, Guo E, Li N, Zhou B, Lu H, Huang J, Xia M, Shan W, Wang B, Li K, Weng D, Xu X, Gao Q, Wang S, ... ... Mills GB, et al. MCP-1/CCR-2 axis in adipocytes and cancer cell respectively facilitates ovarian cancer peritoneal metastasis. Oncogene. PMID 31705064 DOI: 10.1038/S41388-019-1090-1 |
0.335 |
|
| 2019 |
Zhang Z, Lee JH, Ruan H, Ye Y, Krakowiak J, Hu Q, Xiang Y, Gong J, Zhou B, Wang L, Lin C, Diao L, Mills GB, Li W, Han L. Transcriptional landscape and clinical utility of enhancer RNAs for eRNA-targeted therapy in cancer. Nature Communications. 10: 4562. PMID 31594934 DOI: 10.1038/s41467-019-12543-5 |
0.33 |
|
| 2019 |
Liu ZB, Ezzedine NE, Eterovic AK, Ensor JE, Huang HJ, Albanell J, Choi DS, Lluch A, Liu Y, Rojo F, Wong H, Martínez-Dueñas E, Guerrero-Zotano Á, Shao ZM, Darcourt JG, ... Mills GB, et al. Detection of breast cancer stem cell gene mutations in circulating free DNA during the evolution of metastases. Breast Cancer Research and Treatment. PMID 31388936 DOI: 10.1007/S10549-019-05374-X |
0.306 |
|
| 2019 |
Mazumdar A, Tahaney WM, Reddy Bollu L, Poage G, Hill J, Zhang Y, Mills GB, Brown PH. The phosphatase PPM1A inhibits triple negative breast cancer growth by blocking cell cycle progression. Npj Breast Cancer. 5: 22. PMID 31372497 DOI: 10.1038/s41523-019-0118-6 |
0.423 |
|
| 2019 |
Xing Y, Lin NU, Maurer MA, Chen H, Mahvash A, Sahin A, Akcakanat A, Li Y, Abramson V, Litton J, Chavez-MacGregor M, Valero V, Piha-Paul SA, Hong D, Do KA, ... ... Mills GB, et al. Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. Breast Cancer Research : Bcr. 21: 78. PMID 31277699 DOI: 10.1186/S13058-019-1154-8 |
0.302 |
|
| 2019 |
Beaver JA, Coleman RL, Arend RC, Armstrong DK, Bala S, Mills GB, Sood AK, Herzog TJ. Advancing Drug Development in Gynecologic Malignancies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31126961 DOI: 10.1158/1078-0432.Ccr-19-0619 |
0.338 |
|
| 2019 |
Ghandi M, Huang FW, Jané-Valbuena J, Kryukov GV, Lo CC, McDonald ER, Barretina J, Gelfand ET, Bielski CM, Li H, Hu K, Andreev-Drakhlin AY, Kim J, Hess JM, Haas BJ, ... ... Mills GB, et al. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature. PMID 31068700 DOI: 10.1038/S41586-019-1186-3 |
0.332 |
|
| 2019 |
Johansson HJ, Socciarelli F, Vacanti NM, Haugen MH, Zhu Y, Siavelis I, Fernandez-Woodbridge A, Aure MR, Sennblad B, Vesterlund M, Branca RM, Orre LM, Huss M, Fredlund E, Beraki E, ... ... Mills GB, et al. Breast cancer quantitative proteome and proteogenomic landscape. Nature Communications. 10: 1600. PMID 30962452 DOI: 10.1038/S41467-019-09018-Y |
0.359 |
|
| 2019 |
Maric G, Annis MG, MacDonald PA, Russo C, Perkins D, Siwak DR, Mills GB, Siegel PM. GPNMB augments Wnt-1 mediated breast tumor initiation and growth by enhancing PI3K/AKT/mTOR pathway signaling and β-catenin activity. Oncogene. PMID 30914799 DOI: 10.1038/s41388-019-0793-7 |
0.349 |
|
| 2019 |
Konstantinopoulos PA, Barry WT, Birrer M, Westin SN, Cadoo KA, Shapiro GI, Mayer EL, O'Cearbhaill RE, Coleman RL, Kochupurakkal B, Whalen C, Curtis J, Farooq S, Luo W, Eismann J, ... ... Mills GB, et al. Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. The Lancet. Oncology. PMID 30880072 DOI: 10.1016/S1470-2045(18)30905-7 |
0.313 |
|
| 2019 |
Bast RC, Matulonis UA, Sood AK, Ahmed AA, Amobi AE, Balkwill FR, Wielgos-Bonvallet M, Bowtell DDL, Brenton JD, Brugge JS, Coleman RL, Draetta GF, Doberstein K, Drapkin RI, Eckert MA, ... ... Mills GB, et al. Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. Cancer. PMID 30835824 DOI: 10.1002/Cncr.32004 |
0.301 |
|
| 2019 |
Li X, Mak VCY, Zhou Y, Wang C, Wong ESY, Sharma R, Lu Y, Cheung ANY, Mills GB, Cheung LWT. Deregulated Gab2 phosphorylation mediates aberrant AKT and STAT3 signaling upon PIK3R1 loss in ovarian cancer. Nature Communications. 10: 716. PMID 30755611 DOI: 10.1038/s41467-019-08574-7 |
0.326 |
|
| 2019 |
Iavarone C, Zervantonakis IK, Selfors LM, Palakurthi S, Liu JF, Drapkin R, Matulonis UA, Hallberg D, Velculescu VE, Leverson JD, Sampath D, Mills GB, Brugge JS. Combined MEK and BCL-2/XL inhibition is effective in high-grade serous ovarian cancer patient-derived xenograft models and BIM levels are predictive of responsiveness. Molecular Cancer Therapeutics. PMID 30679390 DOI: 10.1158/1535-7163.Mct-18-0413 |
0.405 |
|
| 2019 |
Keck JM, Parmar S, Kong B, Mitri Z, Corless C, Kolodzie A, Creason A, Goecks J, Leyshock P, Siex K, Johnson BE, Patterson J, Heiser L, Olson A, Viehdorfer M, ... ... Mills GB, et al. Abstract 4929: Leveraging multi-omics tumor boards for precision medicine in the OHSU SMMART Treatments Program Cancer Research. 79: 4929-4929. DOI: 10.1158/1538-7445.Sabcs18-4929 |
0.353 |
|
| 2019 |
Labrie M, Ju Z, Litton JK, Kim T, Lee S, Chen K, Soliman PT, Frumovitz M, Meyer LA, Moulder S, Jazaeri AA, Lu KH, Sood AK, Coleman RL, Mills GB, et al. Abstract 2070: Exploration of markers of synergistic lethality of PARP and PI3K-Akt-mTOR inhibitors in women's cancers Cancer Research. 79: 2070-2070. DOI: 10.1158/1538-7445.Am2019-2070 |
0.332 |
|
| 2019 |
Sahni N, McGrail D, Li Y, Mills G, Yi S(. Abstract 1646: Beyond BRCA: Discovery of novel drivers of homologous recombination deficiencies in cancer Cancer Research. 79: 1646-1646. DOI: 10.1158/1538-7445.Am2019-1646 |
0.317 |
|
| 2018 |
Liu S, Li S, Wang B, Liu W, Gagea M, Chen H, Sohn J, Parinyanitikul N, Primeau T, Do KA, Vande Woude GF, Mendelsohn J, Ueno NT, Mills GB, Tripathy D, et al. Cooperative effect of oncogenic MET and PIK3CA in an HGF-dominant environment in breast cancer. Molecular Cancer Therapeutics. PMID 30518672 DOI: 10.1158/1535-7163.MCT-18-0710 |
0.522 |
|
| 2018 |
Holst F, Werner HMJ, Mjøs S, Hoivik EA, Kusonmano K, Wik E, Berg A, Birkeland E, Gibson WJ, Halle MK, Trovik J, Cherniack AD, Kalland KH, Mills GB, Singer CF, et al. Amplification Associates with Aggressive Phenotype but Not Markers of AKT-MTOR Signaling in Endometrial Carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30442683 DOI: 10.1158/1078-0432.Ccr-18-0452 |
0.301 |
|
| 2018 |
Pilié PG, Tang C, Mills GB, Yap TA. State-of-the-art strategies for targeting the DNA damage response in cancer. Nature Reviews. Clinical Oncology. PMID 30356138 DOI: 10.1038/s41571-018-0114-z |
0.369 |
|
| 2018 |
Keene KS, King T, Hwang ES, Peng B, McGuire KP, Tapia C, Zhang H, Bae S, Nakhlis F, Klauber-Demore N, Meszoely I, Sabel MS, Willey SC, Eterovic AK, Hudis C, ... ... Mills GB, et al. Molecular determinants of post-mastectomy breast cancer recurrence. Npj Breast Cancer. 4: 34. PMID 30345349 DOI: 10.1038/s41523-018-0089-z |
0.375 |
|
| 2018 |
Meric-Bernstam F, Zheng X, Shariati M, Damodaran S, Wathoo C, Brusco L, Demirhan ME, Tapia C, Eterovic AK, Basho RK, Ueno NT, Janku F, Sahin A, Rodon J, Broaddus R, ... ... Mills GB, et al. Survival Outcomes by Mutation Status in Metastatic Breast Cancer. Jco Precision Oncology. 2018. PMID 30035249 |
0.308 |
|
| 2018 |
Wang J, Zhao W, Guo H, Fang Y, Stockman SE, Bai S, Ng PK, Li Y, Yu Q, Lu Y, Jeong KJ, Chen X, Gao M, Liang J, Li W, ... ... Mills GB, et al. AKT isoform-specific expression and activation across cancer lineages. Bmc Cancer. 18: 742. PMID 30012111 DOI: 10.1186/s12885-018-4654-5 |
0.354 |
|
| 2018 |
Simpkins F, Jang K, Yoon H, Hew K, Kim M, Azzam DJ, Sun J, Zhao D, Ince TA, Liu W, Guo W, Wei Z, Zhang G, Mills GB, Slingerland JM. Dual Src and MEK inhibition decreases ovarian cancer growth and targets tumor initiating stem-like cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29959144 DOI: 10.1158/1078-0432.Ccr-17-3697 |
0.361 |
|
| 2018 |
Kang MH, Choi H, Oshima M, Cheong JH, Kim S, Lee JH, Park YS, Choi HS, Kweon MN, Pack CG, Lee JS, Mills GB, Myung SJ, Park YY. Estrogen-related receptor gamma functions as a tumor suppressor in gastric cancer. Nature Communications. 9: 1920. PMID 29765046 DOI: 10.1038/s41467-018-04244-2 |
0.353 |
|
| 2018 |
Parekh A, Das S, Parida S, Das CK, Dutta D, Mallick SK, Wu PH, Kumar BNP, Bharti R, Dey G, Banerjee K, Rajput S, Bharadwaj D, Pal I, Dey KK, ... ... Mills GB, et al. Multi-nucleated cells use ROS to induce breast cancer chemo-resistance in vitro and in vivo. Oncogene. PMID 29743594 DOI: 10.1038/S41388-018-0272-6 |
0.393 |
|
| 2018 |
Oh SC, Sohn BH, Cheong JH, Kim SB, Lee JE, Park KC, Lee SH, Park JL, Park YY, Lee HS, Jang HJ, Park ES, Kim SC, Heo J, Chu IS, ... ... Mills GB, et al. Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype. Nature Communications. 9: 1777. PMID 29725014 DOI: 10.1038/s41467-018-04179-8 |
0.348 |
|
| 2018 |
Echevarría-Vargas IM, Reyes-Uribe PI, Guterres AN, Yin X, Kossenkov AV, Liu Q, Zhang G, Krepler C, Cheng C, Wei Z, Somasundaram R, Karakousis G, Xu W, Morrissette JJ, Lu Y, ... Mills GB, et al. Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma. Embo Molecular Medicine. PMID 29650805 DOI: 10.15252/Emmm.201708446 |
0.399 |
|
| 2018 |
Zhang J, Dulak AM, Hattersley MM, Willis BS, Nikkilä J, Wang A, Lau A, Reimer C, Zinda M, Fawell SE, Mills GB, Chen H. BRD4 facilitates replication stress-induced DNA damage response. Oncogene. PMID 29636547 DOI: 10.1038/s41388-018-0194-3 |
0.312 |
|
| 2018 |
Berger AC, Korkut A, Kanchi RS, Hegde AM, Lenoir W, Liu W, Liu Y, Fan H, Shen H, Ravikumar V, Rao A, Schultz A, Li X, Sumazin P, Williams C, ... ... Mills GB, et al. A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. Cancer Cell. PMID 29622464 DOI: 10.1016/J.Ccell.2018.03.014 |
0.356 |
|
| 2018 |
Watson SS, Dane M, Chin K, Tatarova Z, Liu M, Liby T, Thompson W, Smith R, Nederlof M, Bucher E, Kilburn D, Whitman M, Sudar D, Mills GB, Heiser LM, et al. Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes. Cell Systems. PMID 29550255 DOI: 10.1016/j.cels.2018.02.001 |
0.41 |
|
| 2018 |
Lee J, Geiss GK, Demirkan G, Vellano CP, Filanoski B, Lu Y, Ju Z, Yu S, Guo H, Bogatzki LY, Carter WE, Meredith RK, Krishnamurthy S, Ding Z, Beechem JM, ... Mills G, et al. Implementation of a Multiplex and Quantitative Proteomics Platform for Assessing Protein Lysates Using DNA-Barcoded Antibodies. Molecular & Cellular Proteomics : McP. PMID 29531020 DOI: 10.1074/mcp.RA117.000291 |
0.318 |
|
| 2018 |
Ye Y, Xiang Y, Ozguc FM, Kim Y, Liu CJ, Park PK, Hu Q, Diao L, Lou Y, Lin C, Guo AY, Zhou B, Wang L, Chen Z, Takahashi JS, ... Mills GB, et al. The Genomic Landscape and Pharmacogenomic Interactions of Clock Genes in Cancer Chronotherapy. Cell Systems. PMID 29525205 DOI: 10.1016/J.Cels.2018.01.013 |
0.305 |
|
| 2018 |
Jeong BY, Cho KH, Jeong KJ, Park YY, Kim JM, Rha SY, Park CG, Mills GB, Cheong JH, Lee HY. Rab25 augments cancer cell invasiveness through a β1 integrin/EGFR/VEGF-A/Snail signaling axis and expression of fascin. Experimental & Molecular Medicine. 50: e435. PMID 29371698 DOI: 10.1038/emm.2017.248 |
0.34 |
|
| 2018 |
Keene K, King T, Hwang E, Peng B, McGuire K, Tapia C, Zhang H, Bae S, Nakhlis F, Klauber-Demore N, Meszoely I, Sabel, Willey S, Eterovic K, Hudis C, ... ... Mills G, et al. Abstract P3-04-01: Molecular determinants of post-mastectomy breast cancer recurrence Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P3-04-01 |
0.365 |
|
| 2018 |
Berger A, Korkut A, Kanchi RS, Mills GB, Levine DA, Akbani R. Abstract 3303: A comprehensive TCGA Pan-Cancer molecular study of gynecologic and breast cancers Cancer Research. 78: 3303-3303. DOI: 10.1158/1538-7445.Am2018-3303 |
0.35 |
|
| 2018 |
Piha-Paul SA, Xiong WW, Moss T, Mostorino RM, Sedelmeier S, Hess K, Fu S, Hong D, Janku F, Karp D, Naing A, Pant S, Rodon J, Subbiah V, Tsimberidou AM, ... ... Mills GB, et al. Abstract A096: Phase II study of the PARP inhibitor talazoparib in advanced cancer patients with somatic alterations in BRCA1/2, mutations/deletions in PTEN or PTEN loss, aberrations in other BRCA pathway genes, and germline mutations in BRCA1/2 (not breast or ovarian cancer) Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-A096 |
0.303 |
|
| 2017 |
Evans KW, Yuca E, Akcakanat A, Scott SM, Arango NP, Zheng X, Chen K, Tapia C, Tarco E, Eterovic AK, Black DM, Litton JK, Yap TA, Tripathy D, Mills GB, et al. A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 23: 6468-6477. PMID 29093017 DOI: 10.1158/1078-0432.Ccr-17-0615 |
0.427 |
|
| 2017 |
Li J, Akbani R, Zhao W, Lu Y, Weinstein JN, Mills GB, Liang H. Explore, Visualize, and Analyze Functional Cancer Proteomic Data Using the Cancer Proteome Atlas. Cancer Research. 77: e51-e54. PMID 29092939 DOI: 10.1158/0008-5472.CAN-17-0369 |
0.302 |
|
| 2017 |
Mitra S, Montgomery JE, Kolar MJ, Li G, Jeong KJ, Peng B, Verdine GL, Mills GB, Moellering RE. Stapled peptide inhibitors of RAB25 target context-specific phenotypes in cancer. Nature Communications. 8: 660. PMID 28939823 DOI: 10.1038/S41467-017-00888-8 |
0.309 |
|
| 2017 |
Rebecca VW, Nicastri MC, McLaughlin N, Fennelly C, McAfee Q, Ronghe A, Nofal M, Lim CY, Witze E, Chude CI, Zhang G, Alicea GM, Piao S, Murugan S, Ojha R, ... ... Mills GB, et al. A unified approach to targeting the lysosome's degradative and growth signaling roles. Cancer Discovery. PMID 28899863 DOI: 10.1158/2159-8290.Cd-17-0741 |
0.351 |
|
| 2017 |
Zervantonakis IK, Iavarone C, Chen HY, Selfors LM, Palakurthi S, Liu JF, Drapkin R, Matulonis U, Leverson JD, Sampath D, Mills GB, Brugge JS. Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response. Nature Communications. 8: 365. PMID 28848242 DOI: 10.1038/S41467-017-00263-7 |
0.365 |
|
| 2017 |
Federico L, Chong Z, Zhang D, McGrail DJ, Zhao W, Jeong KJ, Vellano CP, Ju Z, Gagea M, Liu S, Mitra S, Dennison JB, Lorenzi PL, Cardnell R, Diao L, ... ... Mills GB, et al. A murine preclinical syngeneic transplantation model for breast cancer precision medicine. Science Advances. 3: e1600957. PMID 28439535 DOI: 10.1126/Sciadv.1600957 |
0.42 |
|
| 2017 |
Yin Y, Shen Q, Zhang P, Tao R, Chang W, Li R, Xie G, Liu W, Zhang L, Kapoor P, Song S, Ajani J, Mills GB, Chen J, Tao K, et al. Chk1 inhibition potentiates the therapeutic efficacy of PARP inhibitor BMN673 in gastric cancer. American Journal of Cancer Research. 7: 473-483. PMID 28401005 |
0.336 |
|
| 2017 |
Bauman JE, Duvvuri U, Gooding WE, Rath TJ, Gross ND, Song J, Jimeno A, Yarbrough WG, Johnson FM, Wang L, Chiosea S, Sen M, Kass J, Johnson JT, Ferris RL, ... ... Mills GB, et al. Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancer. Jci Insight. 2: e90449. PMID 28352657 DOI: 10.1172/Jci.Insight.90449 |
0.338 |
|
| 2017 |
Wang C, Gu C, Jeong KJ, Zhang D, Guo W, Lu Y, Ju Z, Panupinthu N, Yang JY, Gagea M, Ng PK, Zhang F, Mills GB. YAP/TAZ-mediated upregulation of GAB2 leads to increased sensitivity to growth factor-induced activation of the PI3K pathway. Cancer Research. PMID 28202507 DOI: 10.1158/0008-5472.CAN-15-3084 |
0.305 |
|
| 2017 |
George E, Kim H, Krepler C, Wenz B, Makvandi M, Tanyi JL, Brown E, Zhang R, Brafford P, Jean S, Mach RH, Lu Y, Mills GB, Herlyn M, Morgan M, et al. A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers. Jci Insight. 2: e89760. PMID 28097235 DOI: 10.1172/Jci.Insight.89760 |
0.336 |
|
| 2017 |
Holla VR, Elamin YY, Bailey AM, Johnson AM, Litzenburger BC, Khotskaya YB, Sanchez NS, Zeng J, Shufean MA, Shaw KR, Mendelsohn J, Mills GB, Meric-Bernstam F, Simon GR. ALK: a tyrosine kinase target for cancer therapy. Cold Spring Harbor Molecular Case Studies. 3: a001115. PMID 28050598 DOI: 10.1101/mcs.a001115 |
0.357 |
|
| 2017 |
Dave B, Gonzalez DD, Liu ZB, Li X, Wong H, Granados S, Ezzedine NE, Sieglaff DH, Ensor JE, Miller KD, Radovich M, KarinaEtrovic A, Gross SS, Elemento O, Mills GB, et al. Role of RPL39 in Metaplastic Breast Cancer. Journal of the National Cancer Institute. 109. PMID 28040796 DOI: 10.1093/Jnci/Djw292 |
0.323 |
|
| 2017 |
Albanell J, Gonzalez A, Gonzalez-Angulo AM, Eterovic AK, Duenas EM, Zheng X, Guerrero A, Liu S, Pérez-Carrión R, Chen K, Chacon JI, Mills GB, Novoa SA, Blancas I, Sanchez-Arago M, et al. Genomic alterations driving breast cancer (BC) metastases and their relationship with the subtype switch in the GEICAM ConvertHER study. Journal of Clinical Oncology. 35: 1017-1017. DOI: 10.1200/Jco.2017.35.15_Suppl.1017 |
0.342 |
|
| 2017 |
Evans K, Yuca E, Akcakanat A, Scott S, Arango NP, Zheng X, Chen K, Tapia C, Tarco E, Eterovic A, Black D, Jennifer L, Tripathy D, Mills G, Meric-Bernstam F. Abstract P4-06-04: Triple negative breast cancer patient-derived xenografts: Molecular characteristics and sensitivity to emerging therapies Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P4-06-04 |
0.31 |
|
| 2017 |
Huo D, Hu H, Rhie S, Gamazon E, Cherniack A, Liu J, Yoshimatsu T, Pitt J, Hoadley K, Troester M, Ru Y, Lichtenberg T, Sturtz L, Shelley C, Mills G, et al. Abstract P1-05-11: Comprehensive comparison of breast cancer molecular portraits by African and European ancestry in the cancer genome atlas Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P1-05-11 |
0.306 |
|
| 2017 |
Zervantonakis IK, Iavarone C, Chen H, Leverson J, Sampath D, Palakurthi S, Drapkin R, Liu JF, Matulonis U, Mills G, Brugge JS. Abstract PR01: Systems analysis of signaling pathway adaptation to design effective PI3K-based combination therapies using ovarian cancer patient-derived xenografts Cancer Research. 77. DOI: 10.1158/1538-7445.Epso16-Pr01 |
0.382 |
|
| 2017 |
Konstantinopoulos PA, Barry WT, Birrer M, Westin SN, Farooq S, Cadoo K, Whalen C, Luo W, Liu H, Aghajanian C, Solit DB, Mills GB, Taylor BS, Won H, Berger MF, et al. Abstract CT008: Phase I study of the alpha specific PI3-Kinase inhibitor BYL719 and the poly (ADP-Ribose) polymerase (PARP) inhibitor olaparib in recurrent ovarian and breast cancer: Analysis of the dose escalation and ovarian cancer expansion cohort Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Ct008 |
0.325 |
|
| 2017 |
Mazumdar A, Hill J, Zhang Y, Bollu LR, Tsimelzon A, Chang J, Mills G, Brown P. Abstract 5525: Induced expression of PPM1A in ER-negative breast cancer cells inhibits growth by suppressing CDK phosphorylation Cancer Research. 77: 5525-5525. DOI: 10.1158/1538-7445.Am2017-5525 |
0.341 |
|
| 2017 |
Takahashi N, Chen H, Harris I, Stover D, Bronson R, Deraedt T, Cichowski K, Welm A, Mills G, Brugge J. Abstract 5478: The TRPA1 Ca2+-permeable channel mediates a non-canonical redox adaptation in cancer cells Cancer Research. 77: 5478-5478. DOI: 10.1158/1538-7445.Am2017-5478 |
0.325 |
|
| 2017 |
Iavarone C, Zervantonakis I, Selfors LM, Palakurthi S, Liu JF, Matulonis UA, Drapkin RI, Mills GB, Leverson JD, Sampath D, Brugge JS. Abstract 4033: Combined MEK and BCL-2/XLinhibition as a potential drug combination for the treatment of high-grade serous ovarian cancer Cancer Research. 77: 4033-4033. DOI: 10.1158/1538-7445.Am2017-4033 |
0.384 |
|
| 2017 |
Westin S, Litton J, Williams R, Soliman P, Frumovitz M, Schmeler K, Jazaeri A, Sood A, Lu K, Moulder S, Murthy R, Rodriguez A, Samuel C, Engerman L, Cyriac A, ... ... Mills G, et al. 391PPhase I expansion of olaparib (PARP inhibitor) and AZD5363 (AKT inhibitor) in recurrent ovarian, endometrial and triple negative breast cancer Annals of Oncology. 28. DOI: 10.1093/Annonc/Mdx367.025 |
0.329 |
|
| 2016 |
Muranen T, Selfors LM, Hwang J, Gallegos LL, Coloff JL, Thoreen CC, Kang SA, Sabatini DM, Mills GB, Brugge JS. ERK and p38 MAPK Activities Determine Sensitivity to PI3K/mTOR Inhibition via Regulation of MYC and YAP. Cancer Research. PMID 27913436 DOI: 10.1158/0008-5472.Can-16-0155 |
0.36 |
|
| 2016 |
Basho RK, Gagliato DM, Ueno NT, Wathoo C, Chen H, Shariati M, Wei C, Alvarez RH, Moulder SL, Sahin AA, Roy-Chowdhuri S, Chavez-MacGregor M, Litton JK, Valero V, Luthra R, ... ... Mills GB, et al. Clinical outcomes based on multigene profiling in metastatic breast cancer patients. Oncotarget. PMID 27806348 DOI: 10.18632/Oncotarget.12987 |
0.314 |
|
| 2016 |
Verma N, Müller AK, Kothari C, Panayotopoulou E, Kedan A, Selitrennik M, Mills GB, Nguyen LK, Shin S, Karn T, Holtrich U, Lev S. Targeting of PYK2 synergizes with EGFR antagonists in basal-like TNBC and circumvents HER3-associated resistance via the NEDD4-NDRG1 axis. Cancer Research. PMID 27793840 DOI: 10.1158/0008-5472.Can-16-1797 |
0.708 |
|
| 2016 |
Lu Y, Ling S, Hegde AM, Byers LA, Coombes K, Mills GB, Akbani R. Using reverse-phase protein arrays as pharmacodynamic assays for functional proteomics, biomarker discovery, and drug development in cancer. Seminars in Oncology. 43: 476-83. PMID 27663479 DOI: 10.1053/j.seminoncol.2016.06.005 |
0.311 |
|
| 2016 |
Kang MH, Jeong KJ, Kim WY, Lee HJ, Gong G, Suh N, Győrffy B, Kim S, Jeong SY, Mills GB, Park YY. Musashi RNA-binding protein 2 regulates estrogen receptor 1 function in breast cancer. Oncogene. PMID 27593929 DOI: 10.1038/onc.2016.327 |
0.368 |
|
| 2016 |
Liu JF, Palakurthi S, Zeng Q, Zhou S, Ivanova E, Huang W, Zervantonakis IK, Selfors LM, Shen Y, Pritchard CC, Zheng M, Adleff V, Papp E, Piao H, Novak M, ... ... Mills GB, et al. Establishment of patient-derived tumor xenograft models of epithelial ovarian cancer for pre-clinical evaluation of novel therapeutics. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27573169 DOI: 10.1158/1078-0432.Ccr-16-1237 |
0.328 |
|
| 2016 |
Mazumdar A, Poage GM, Shepherd J, Tsimelzon A, Hartman ZC, Den Hollander P, Hill J, Zhang Y, Chang J, Hilsenbeck SG, Fuqua S, Kent Osborne C, Mills GB, Brown PH. Analysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasion. Breast Cancer Research and Treatment. PMID 27393618 DOI: 10.1007/S10549-016-3892-Y |
0.382 |
|
| 2016 |
Haukaas TH, Euceda LR, Giskeødegård GF, Lamichhane S, Krohn M, Jernström S, Aure MR, Lingjærde OC, Schlichting E, Garred Ø, Due EU, Mills GB, Sahlberg KK, Børresen-Dale AL, Bathen TF, et al. Metabolic clusters of breast cancer in relation to gene- and protein expression subtypes. Cancer & Metabolism. 4: 12. PMID 27350877 DOI: 10.1186/s40170-016-0152-x |
0.373 |
|
| 2016 |
Mitra S, Federico L, Zhao W, Dennison J, Sarkar TR, Zhang F, Takiar V, Cheng KW, Mani S, Lee JS, Mills GB. Rab25 acts as an oncogene in luminal B breast cancer and is causally associated with Snail driven EMT. Oncotarget. PMID 27259233 DOI: 10.18632/Oncotarget.9730 |
0.391 |
|
| 2016 |
Dennison JB, Shahmoradgoli M, Liu W, Ju Z, Meric-Bernstam F, Perou CM, Sahin A, Welm AL, Oesterreich S, Sikora MJ, Brown RE, Mills GB. High intra-tumoral stromal content defines Reactive breast cancer as a low-risk breast cancer subtype. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27172895 DOI: 10.1158/1078-0432.Ccr-16-0171 |
0.319 |
|
| 2016 |
Chaluvally-Raghavan P, Jeong KJ, Pradeep S, Silva AM, Yu S, Liu W, Moss T, Rodriguez-Aguayo C, Zhang D, Ram P, Liu J, Lu Y, Lopez-Berestein G, Calin GA, Sood AK, ... Mills GB, et al. Direct Upregulation of STAT3 by MicroRNA-551b-3p Deregulates Growth and Metastasis of Ovarian Cancer. Cell Reports. PMID 27160903 DOI: 10.1016/J.Celrep.2016.04.034 |
0.307 |
|
| 2016 |
Turpin J, Ling C, Crosby EJ, Hartman ZC, Simond AM, Chodosh LA, Rennhack JP, Andrechek ER, Ozcelik J, Hallett M, Mills GB, Cardiff RD, Gray JW, Griffith OL, Muller WJ. The ErbB2ΔEx16 splice variant is a major oncogenic driver in breast cancer that promotes a pro-metastatic tumor microenvironment. Oncogene. PMID 27157621 DOI: 10.1038/Onc.2016.129 |
0.381 |
|
| 2016 |
Wang C, Zhu X, Feng W, Yu Y, Jeong K, Guo W, Lu Y, Mills GB. Verteporfin inhibits YAP function through up-regulating 14-3-3σ sequestering YAP in the cytoplasm. American Journal of Cancer Research. 6: 27-37. PMID 27073720 |
0.398 |
|
| 2016 |
Boulay PL, Mitchell L, Turpin J, Huot-Marchand JÉ, Lavoie C, Sanguin-Gendreau V, Jones L, Mitra S, Livingstone JM, Campbell S, Hallett M, Mills GB, Park M, Chodosh L, Strathdee D, et al. Rab11-FIP1C is a critical negative regulator in ErbB2-mediated mammary tumor progression. Cancer Research. PMID 26933086 DOI: 10.1158/0008-5472.Can-15-2782 |
0.395 |
|
| 2016 |
Lucenay KS, Doostan I, Karakas C, Bui T, Ding Z, Mills GB, Hunt KK, Keyomarsi K. Cyclin E associates with the lipogenic enzyme ATP-citrate lyase to enable malignant growth of breast cancer cells. Cancer Research. PMID 26928812 DOI: 10.1158/0008-5472.Can-15-1646 |
0.326 |
|
| 2016 |
den Hollander P, Rawls K, Tsimelzon A, Shepherd J, Mazumdar A, Hill J, Fuqua SA, Chang JC, Osborne CK, Hilsenbeck SG, Mills GB, Brown PH. Phosphatase PTP4A3 promotes triple-negative breast cancer growth and predicts poor patient survival. Cancer Research. PMID 26921331 DOI: 10.1158/0008-5472.Can-14-0673 |
0.451 |
|
| 2016 |
Tsang YH, Dogruluk T, Tedeschi PM, Wardwell-Ozgo J, Lu H, Espitia M, Nair N, Minelli R, Chong Z, Chen F, Chang QE, Dennison JB, Dogruluk A, Li M, Ying H, ... ... Mills GB, et al. Functional annotation of rare gene aberration drivers of pancreatic cancer. Nature Communications. 7: 10500. PMID 26806015 DOI: 10.1038/Ncomms10500 |
0.333 |
|
| 2016 |
Marcotte R, Sayad A, Brown KR, Sanchez-Garcia F, Reimand J, Haider M, Virtanen C, Bradner JE, Bader GD, Mills GB, Pe'er D, Moffat J, Neel BG. Functional Genomic Landscape of Human Breast Cancer Drivers, Vulnerabilities, and Resistance. Cell. 164: 293-309. PMID 26771497 DOI: 10.1016/J.Cell.2015.11.062 |
0.381 |
|
| 2016 |
Evans KW, Yuca E, Scott SM, Paez NA, Zheng X, Chen K, Gonzales L, Tapia C, Tarco E, Black DM, Mills GB, Meric-Bernstam F. Abstract A39: Patient-derived xenografts to test emerging therapies for triple negative breast cancer Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Pdx16-A39 |
0.418 |
|
| 2016 |
George E, Kim H, Tanyi J, Ragland R, Brown E, Zhang R, Brafford P, Sproesser K, Beqiri M, Vultur A, Krepler C, Weis B, Nathanson K, Lu Y, Mills G, et al. Abstract A02: A novel orthotopic ovarian patient derived xenograft model platform to investigate novel therapies for BRCA deficient ovarian cancers Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Pdx16-A02 |
0.33 |
|
| 2016 |
Iavarone C, Zervantonakis I, Chen H, Palakurthi SS, Liu JF, Matulonis UA, Drapkin RI, Mills GB, Leverson JD, Sampath D, Brugge JS. Abstract B48: Design of effective combination therapies for high-grade serous ovarian cancer using patient-derived xenograft models. Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Ovca15-B48 |
0.398 |
|
| 2016 |
Mitra S, Federico L, Mills GB. Abstract B40: Transcription factor Snail mediates EMT by altering vesicular trafficking protein Rab25 Molecular Cancer Research. 14. DOI: 10.1158/1557-3125.Advbc15-B40 |
0.382 |
|
| 2016 |
Yang C, Gonzalez AM, Ueno NT, Liu S, Zhang J, Mills GB, Mendelsohn J, Ram P. Abstract 668: Induction of mammary carcinoma in tetracycline-inducible cMET(T1010I) transgenic mice Cancer Research. 76: 668-668. DOI: 10.1158/1538-7445.Am2016-668 |
0.335 |
|
| 2016 |
George E, Kim H, Tanyi J, Ragland R, Zhang R, Bradford P, Krepler C, Nathanson K, Wenz B, Lu Y, Mills G, Morgan M, Simpkins F. Abstract 4835: Targeting the ATR/CHK1 axis in combination with PARP inhibition is more effective than PARP inhibition alone in BRCA mutant models Cancer Research. 76: 4835-4835. DOI: 10.1158/1538-7445.Am2016-4835 |
0.373 |
|
| 2016 |
Iavarone C, Zervantonakis I, Chen H, Palakurthi SS, Liu JF, Matulonis U, Drapkin R, Mills G, Leverson J, Sampath D, Brugge J. Abstract 3843: Design of effective combination therapies for high-grade serous ovarian cancer using patient-derived xenograft models Cancer Research. 76: 3843-3843. DOI: 10.1158/1538-7445.Am2016-3843 |
0.43 |
|
| 2015 |
Rupaimoole R, Lee J, Haemmerle M, Ling H, Previs RA, Pradeep S, Wu SY, Ivan C, Ferracin M, Dennison JB, Millward NM, Nagaraja AS, Gharpure KM, McGuire M, Sam N, ... ... Mills GB, et al. Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis. Cell Reports. PMID 26686630 DOI: 10.1016/J.Celrep.2015.11.047 |
0.301 |
|
| 2015 |
Mo W, Liu Q, Lin CC, Dai H, Peng Y, Liang Y, Peng G, Meric-Bernstam F, Mills GB, Li K, Lin SY. mTOR inhibitors suppress homologous recombination repair and synergize with PARP inhibitors via regulating SUV39H1 in BRCA-proficient triple-negative breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26546619 DOI: 10.1158/1078-0432.CCR-15-1772 |
0.371 |
|
| 2015 |
Cheraghchi-Bashi A, Parker CA, Curry E, Salazar JF, Gungor H, Saleem A, Cunnea P, Rama N, Salinas C, Mills GB, Morris SR, Kumar R, Gabra H, Stronach EA. A putative biomarker signature for clinically effective AKT inhibition: correlation of in vitro, in vivo and clinical data identifies the importance of modulation of the mTORC1 pathway. Oncotarget. PMID 26497682 DOI: 10.18632/oncotarget.6153 |
0.311 |
|
| 2015 |
Hew K, Miller PC, El-Ashry D, Sun J, Besser AH, Ince TA, Gu M, Wei Z, Zhang G, Brafford PA, Guo W, Lu Y, Mills GB, Slingerland JM, Simpkins F. MAPK activation predicts poor outcome and the MEK inhibitor, selumetininb, reverses antiestrogen resistance in high grade serous ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26482043 DOI: 10.1158/1078-0432.Ccr-15-0534 |
0.326 |
|
| 2015 |
Ciriello G, Gatza ML, Beck AH, Wilkerson MD, Rhie SK, Pastore A, Zhang H, McLellan M, Yau C, Kandoth C, Bowlby R, Shen H, Hayat S, Fieldhouse R, Lester SC, ... ... Mills GB, et al. Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. Cell. 163: 506-19. PMID 26451490 DOI: 10.1016/J.Cell.2015.09.033 |
0.357 |
|
| 2015 |
McAuliffe PF, Evans KW, Akcakanat A, Chen K, Zheng X, Zhao H, Eterovic AK, Sangai T, Holder AM, Sharma C, Chen H, Do KA, Tarco E, Gagea M, Naff KA, ... ... Mills GB, et al. Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes. Plos One. 10: e0136851. PMID 26325287 DOI: 10.1371/Journal.Pone.0136851 |
0.368 |
|
| 2015 |
Nanos-Webb A, Bui T, Karakas C, Zhang D, Carey JP, Mills GB, Hunt KK, Keyomarsi K. PKCiota promotes ovarian tumor progression through deregulation of cyclin E. Oncogene. PMID 26279297 DOI: 10.1038/Onc.2015.301 |
0.301 |
|
| 2015 |
Guo H, German P, Bai S, Barnes S, Guo W, Qi X, Lou H, Liang J, Jonasch E, Mills GB, Ding Z. The PI3K/AKT Pathway and Renal Cell Carcinoma. Journal of Genetics and Genomics = Yi Chuan Xue Bao. 42: 343-53. PMID 26233890 DOI: 10.1016/j.jgg.2015.03.003 |
0.328 |
|
| 2015 |
Timsah Z, Ahmed Z, Ivan C, Berrout J, Gagea M, Zhou Y, Pena GN, Hu X, Vallien C, Kingsley CV, Lu Y, Hancock JF, Liu J, Gladden AB, Mills GB, et al. Grb2 depletion under non-stimulated conditions inhibits PTEN, promotes Akt-induced tumor formation and contributes to poor prognosis in ovarian cancer. Oncogene. PMID 26212011 DOI: 10.1038/Onc.2015.279 |
0.334 |
|
| 2015 |
Korkola JE, Collisson EA, Heiser L, Oates C, Bayani N, Itani S, Esch A, Thompson W, Griffith OL, Wang NJ, Kuo WL, Cooper B, Billig J, Ziyad S, Hung JL, ... ... Mills GB, et al. Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer. Plos One. 10: e0133219. PMID 26181325 DOI: 10.1371/Journal.Pone.0133219 |
0.374 |
|
| 2015 |
Zhao J, Zhao D, Poage GM, Mazumdar A, Zhang Y, Hill JL, Hartman ZC, Savage MI, Mills GB, Brown PH. Death-associated protein kinase 1 promotes growth of p53-mutant cancers. The Journal of Clinical Investigation. 125: 2707-20. PMID 26075823 DOI: 10.1172/JCI70805 |
0.412 |
|
| 2015 |
Jeon YJ, Khelifa S, Ratnikov B, Scott DA, Feng Y, Parisi F, Ruller C, Lau E, Kim H, Brill LM, Jiang T, Rimm DL, Cardiff RD, Mills GB, Smith JW, et al. Regulation of glutamine carrier proteins by RNF5 determines breast cancer response to ER stress-inducing chemotherapies. Cancer Cell. 27: 354-69. PMID 25759021 DOI: 10.1016/J.Ccell.2015.02.006 |
0.308 |
|
| 2015 |
Pettazzoni P, Viale A, Shah P, Carugo A, Ying H, Wang H, Genovese G, Seth S, Minelli R, Green T, Huang-Hobbs E, Corti D, Sanchez N, Nezi L, Marchesini M, ... ... Mills GB, et al. Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer. Cancer Research. 75: 1091-101. PMID 25736685 DOI: 10.1158/0008-5472.Can-14-1854 |
0.364 |
|
| 2015 |
Gonzalez-Angulo AM, Krop I, Akcakanat A, Chen H, Liu S, Li Y, Culotta KS, Tarco E, Piha-Paul S, Moulder-Thompson S, Velez-Bravo V, Sahin AA, Doyle LA, Do KA, Winer EP, ... Mills GB, et al. SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer. Journal of the National Cancer Institute. 107. PMID 25688104 DOI: 10.1093/Jnci/Dju493 |
0.318 |
|
| 2015 |
Liu S, Meric-Bernstam F, Parinyanitikul N, Wang B, Eterovic AK, Zheng X, Gagea M, Chavez-MacGregor M, Ueno NT, Lei X, Zhou W, Nair L, Tripathy D, Brown PH, Hortobagyi GN, ... ... Mills GB, et al. Functional consequence of the MET-T1010I polymorphism in breast cancer. Oncotarget. 6: 2604-14. PMID 25605252 DOI: 10.18632/Oncotarget.3094 |
0.353 |
|
| 2015 |
Boggs AE, Vitolo MI, Whipple RA, Charpentier MS, Goloubeva OG, Ioffe OB, Tuttle KC, Slovic J, Lu Y, Mills GB, Martin SS. α-Tubulin acetylation elevated in metastatic and basal-like breast cancer cells promotes microtentacle formation, adhesion, and invasive migration. Cancer Research. 75: 203-15. PMID 25503560 DOI: 10.1158/0008-5472.Can-13-3563 |
0.329 |
|
| 2015 |
Chiu HS, Llobet-Navas D, Yang X, Chung WJ, Ambesi-Impiombato A, Iyer A, Kim HR, Seviour EG, Luo Z, Sehgal V, Moss T, Lu Y, Ram P, Silva J, Mills GB, et al. Cupid: simultaneous reconstruction of microRNA-target and ceRNA networks. Genome Research. 25: 257-67. PMID 25378249 DOI: 10.1101/Gr.178194.114 |
0.399 |
|
| 2015 |
Dillon LM, Bean JR, Yang W, Shee K, Symonds LK, Balko JM, McDonald WH, Liu S, Gonzalez-Angulo AM, Mills GB, Arteaga CL, Miller TW. P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer. Oncogene. 34: 3968-76. PMID 25284585 DOI: 10.1038/Onc.2014.328 |
0.389 |
|
| 2015 |
Burstein MD, Tsimelzon A, Poage GM, Covington KR, Contreras A, Fuqua SA, Savage MI, Osborne CK, Hilsenbeck SG, Chang JC, Mills GB, Lau CC, Brown PH. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 1688-98. PMID 25208879 DOI: 10.1158/1078-0432.Ccr-14-0432 |
0.371 |
|
| 2015 |
Choi MJ, Cho KH, Lee S, Bae YJ, Jeong KJ, Rha SY, Choi EJ, Park JH, Kim JM, Lee JS, Mills GB, Lee HY. hTERT mediates norepinephrine-induced Slug expression and ovarian cancer aggressiveness. Oncogene. 34: 3402-12. PMID 25151968 DOI: 10.1038/onc.2014.270 |
0.324 |
|
| 2015 |
Labidi-Galy SI, Clauss A, Ng V, Duraisamy S, Elias KM, Piao HY, Bilal E, Davidowitz RA, Lu Y, Badalian-Very G, Györffy B, Kang UB, Ficarro S, Ganesan S, Mills GB, et al. Elafin drives poor outcome in high-grade serous ovarian cancers and basal-like breast tumors. Oncogene. 34: 373-83. PMID 24469047 DOI: 10.1038/Onc.2013.562 |
0.409 |
|
| 2015 |
Telli ML, Timms K, Reid JE, Neff C, Abkevich V, Gutin A, Sangale Z, Illiev D, Jones JT, Hennessy B, Lanchbury JS, Mills GB, Hartman A, Ford JM. Combined Homologous Recombination Deficiency (HRD) scores and response to neoadjuvant platinum-based chemotherapy in triple-negative and/or BRCA1/2 mutation-associated breast cancer. Journal of Clinical Oncology. 33: 1018-1018. DOI: 10.1200/JCO.2015.33.15_SUPPL.1018 |
0.312 |
|
| 2015 |
Simpkins F, Hew K, Azzam D, Wei Z, Zhang G, Sun J, Zhang D, Jang K, Liu W, Lu Y, Mills G, Tan I, Slingerland J. Abstract POSTER-THER-1431: Combined Src and MEK inhibition decreases ovarian cancer (OVCA) cell growth, tumorigenicity and aldehyde dehydrogenase positive tumor-initiating-cells Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Ovcasymp14-Poster-Ther-1431 |
0.36 |
|
| 2015 |
Hew K, Miller P, Sun J, Wei Z, Zhang G, Lu Y, Mills G, Slingerland J, El-Ashry D, Simpkins F. Abstract AS31: MEK inhibition reverses antiestrogen resistance in ovarian cancer (OVCA) via alteration of cell cycle pathways and MAPK/estrogen regulated gene expression Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Ovcasymp14-As31 |
0.41 |
|
| 2015 |
Muranen T, Selfors LM, Thoreen CC, Gallegos LL, Coloff JL, Mills GB, Brugge JS. Abstract PR03: The Hippo pathway effector YAP1 contributes to escape from proliferation arrest under chronic PI3K/mTOR inhibition Molecular Cancer Therapeutics. 14. DOI: 10.1158/1538-8514.Pi3K14-Pr03 |
0.35 |
|
| 2015 |
Scott K, Tsang YH, Dogruluk T, Tedeschi P, Bertino J, Mills G. Abstract PR06: Functional prioritization of rare gene aberration drivers of cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Transcagen-Pr06 |
0.345 |
|
| 2015 |
Gonzalez-Angulo AM, Lluch A, Eterovic AK, Guerrero A, Zheng X, Perez R, Liu S, Chacón JI, Chen K, Antolin S, Mills GB, Ferrer J, Burgues O, Bermejo B, Munoz E, et al. Abstract PD3-6: ConvertHER: Evolution of genomic alterations from primary to metastatic breast cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-Pd3-6 |
0.371 |
|
| 2015 |
Federico L, Jeong KJ, Zhang D, Ju Z, Chong Z, Dennison JB, Mills GB. Abstract P6-06-01: Studies on tumor heterogeneity using a preclinical model of breast cancer caused by genetic alteration of the ATX-LPA axis Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P6-06-01 |
0.349 |
|
| 2015 |
Lehmann BD, Bauer JA, Schafer JM, Pendleton CS, Tang L, Johnson KC, Chen X, Balko JM, Gomez H, Arteaga CL, Mills GB, Sanders ME, Pietenpol JA. Abstract P3-04-03: PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P3-04-03 |
0.389 |
|
| 2015 |
Mitra S, Federico L, Roysarkar T, Mani S, Mills GB. Abstract 4040: Transcription factor Snail mediates EMT by altering vesicular trafficking protein Rab25 Cancer Research. 75: 4040-4040. DOI: 10.1158/1538-7445.Am2015-4040 |
0.377 |
|
| 2015 |
Balaji K, Cardnell R, Diao L, Tong P, Mak M, Fan YH, Masrorpour F, Warner SL, Bearss DJ, Wistuba I, Mills GB, Heymach J, Keyomarsi K, Wang J, Byers LA. Abstract 3579: Identification of biomarkers of AXL-mediated drug resistance in head and neck squamous cell carcinoma Cancer Research. 75: 3579-3579. DOI: 10.1158/1538-7445.Am2015-3579 |
0.412 |
|
| 2015 |
Raghavan PC, Pradeep S, Lu Y, Sood A, Mills G. Abstract 3072: miR-551b amplification regulates STAT3 expression and resistance to anoikis of ovarian cancer cells Cancer Research. 75: 3072-3072. DOI: 10.1158/1538-7445.Am2015-3072 |
0.312 |
|
| 2015 |
Krepler C, Xiao M, Sproesser K, Brafford P, Shannan B, Beqiri M, Xu W, Garman B, Nathanson KL, Xu X, Karakousis G, Mills GB, Lu Y, Caponigro G, Boehm M, et al. Abstract 2842: Personalized pre-clinical trials in BRAF inhibitor resistant patient derived xenograft models of melanoma identify c-Met as an effective second line combination therapy target Cancer Research. 75: 2842-2842. DOI: 10.1158/1538-7445.Am2015-2842 |
0.337 |
|
| 2014 |
Schwarz LJ, Fox EM, Balko JM, Garrett JT, Kuba MG, Estrada MV, González-Angulo AM, Mills GB, Red-Brewer M, Mayer IA, Abramson V, Rizzo M, Kelley MC, Meszoely IM, Arteaga CL. LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer. The Journal of Clinical Investigation. 124: 5490-502. PMID 25401474 DOI: 10.1172/Jci72573 |
0.389 |
|
| 2014 |
Kim TH, Yoo JY, Kim HI, Gilbert J, Ku BJ, Li J, Mills GB, Broaddus RR, Lydon JP, Lim JM, Yoon HG, Jeong JW. Mig-6 suppresses endometrial cancer associated with Pten deficiency and ERK activation. Cancer Research. 74: 7371-82. PMID 25377472 DOI: 10.1158/0008-5472.CAN-14-0794 |
0.349 |
|
| 2014 |
Sohn J, Liu S, Parinyanitikul N, Lee J, Hortobagyi GN, Mills GB, Ueno NT, Gonzalez-Angulo AM. cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer. Journal of Cancer. 5: 745-53. PMID 25368674 DOI: 10.7150/jca.9696 |
0.393 |
|
| 2014 |
Gopal YN, Rizos H, Chen G, Deng W, Frederick DT, Cooper ZA, Scolyer RA, Pupo G, Komurov K, Sehgal V, Zhang J, Patel L, Pereira CG, Broom BM, Mills GB, et al. Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1α and oxidative phosphorylation in melanoma. Cancer Research. 74: 7037-47. PMID 25297634 DOI: 10.1158/0008-5472.CAN-14-1392 |
0.333 |
|
| 2014 |
Fu X, Creighton CJ, Biswal NC, Kumar V, Shea M, Herrera S, Contreras A, Gutierrez C, Wang T, Nanda S, Giuliano M, Morrison G, Nardone A, Karlin KL, Westbrook TF, ... ... Mills GB, et al. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase. Breast Cancer Research : Bcr. 16: 430. PMID 25212826 DOI: 10.1186/S13058-014-0430-X |
0.39 |
|
| 2014 |
Mazumdar T, Byers LA, Ng PK, Mills GB, Peng S, Diao L, Fan YH, Stemke-Hale K, Heymach JV, Myers JN, Glisson BS, Johnson FM. A comprehensive evaluation of biomarkers predictive of response to PI3K inhibitors and of resistance mechanisms in head and neck squamous cell carcinoma. Molecular Cancer Therapeutics. 13: 2738-50. PMID 25193510 DOI: 10.1158/1535-7163.Mct-13-1090 |
0.332 |
|
| 2014 |
Peng G, Woodman SE, Mills GB. RADical response puts an exceptional responder in CHKmate: a synthetic lethal curative response to DNA-damaging chemotherapy? Cancer Discovery. 4: 988-90. PMID 25185187 DOI: 10.1158/2159-8290.CD-14-0738 |
0.322 |
|
| 2014 |
He N, Kim N, Song M, Park C, Kim S, Park EY, Yim HY, Kim K, Park JH, Kim KI, Zhang F, Mills GB, Yoon S. Integrated analysis of transcriptomes of cancer cell lines and patient samples reveals STK11/LKB1-driven regulation of cAMP phosphodiesterase-4D. Molecular Cancer Therapeutics. 13: 2463-73. PMID 25122068 DOI: 10.1158/1535-7163.Mct-14-0297 |
0.351 |
|
| 2014 |
Lehmann BD, Bauer JA, Schafer JM, Pendleton CS, Tang L, Johnson KC, Chen X, Balko JM, Gómez H, Arteaga CL, Mills GB, Sanders ME, Pietenpol JA. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. Breast Cancer Research : Bcr. 16: 406. PMID 25103565 DOI: 10.1186/S13058-014-0406-X |
0.369 |
|
| 2014 |
Muranen T, Meric-Bernstam F, Mills GB. Promising rationally derived combination therapy with PI3K and CDK4/6 inhibitors. Cancer Cell. 26: 7-9. PMID 25026206 DOI: 10.1016/j.ccr.2014.06.020 |
0.372 |
|
| 2014 |
O'Leary PC, Terrile M, Bajor M, Gaj P, Hennessy BT, Mills GB, Zagozdzon A, O'Connor DP, Brennan DJ, Connor K, Li J, Gonzalez-Angulo AM, Sun HD, Pu JX, Pontén F, et al. Peroxiredoxin-1 protects estrogen receptor α from oxidative stress-induced suppression and is a protein biomarker of favorable prognosis in breast cancer. Breast Cancer Research : Bcr. 16: R79. PMID 25011585 DOI: 10.1186/bcr3691 |
0.338 |
|
| 2014 |
Liu S, Meng X, Chen H, Liu W, Miller T, Murph M, Lu Y, Zhang F, Gagea M, Arteaga CL, Mills GB, Meric-Bernstam F, González-Angulo AM. Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer. Oncotarget. 5: 9049-64. PMID 24979294 DOI: 10.18632/Oncotarget.2022 |
0.409 |
|
| 2014 |
Hsu YH, Yao J, Chan LC, Wu TJ, Hsu JL, Fang YF, Wei Y, Wu Y, Huang WC, Liu CL, Chang YC, Wang MY, Li CW, Shen J, Chen MK, ... ... Mills GB, et al. Definition of PKC-α, CDK6, and MET as therapeutic targets in triple-negative breast cancer. Cancer Research. 74: 4822-35. PMID 24970481 DOI: 10.1158/0008-5472.Can-14-0584 |
0.435 |
|
| 2014 |
Lorenzi PL, Claerhout S, Mills GB, Weinstein JN. A curated census of autophagy-modulating proteins and small molecules: candidate targets for cancer therapy. Autophagy. 10: 1316-26. PMID 24906121 DOI: 10.4161/Auto.28773 |
0.361 |
|
| 2014 |
Meric-Bernstam F, Akcakanat A, Chen H, Sahin A, Tarco E, Carkaci S, Adrada BE, Singh G, Do KA, Garces ZM, Mittendorf E, Babiera G, Bedrosian I, Hwang R, Krishnamurthy S, ... ... Mills GB, et al. Influence of biospecimen variables on proteomic biomarkers in breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 3870-83. PMID 24895461 DOI: 10.1158/1078-0432.CCR-13-1507 |
0.375 |
|
| 2014 |
Lee J, Tiwari A, Shum V, Mills GB, Mancini MA, Igoshin OA, Balázsi G. Unraveling the regulatory connections between two controllers of breast cancer cell fate. Nucleic Acids Research. 42: 6839-49. PMID 24792166 DOI: 10.1093/Nar/Gku360 |
0.307 |
|
| 2014 |
Davidowitz RA, Selfors LM, Iwanicki MP, Elias KM, Karst A, Piao H, Ince TA, Drage MG, Dering J, Konecny GE, Matulonis U, Mills GB, Slamon DJ, Drapkin R, Brugge JS. Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance. The Journal of Clinical Investigation. 124: 2611-25. PMID 24762435 DOI: 10.1172/Jci69815 |
0.306 |
|
| 2014 |
Gonzalez-Angulo AM, Akcakanat A, Liu S, Green MC, Murray JL, Chen H, Palla SL, Koenig KB, Brewster AM, Valero V, Ibrahim NK, Moulder-Thompson S, Litton JK, Tarco E, Moore J, ... ... Mills GB, et al. Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 25: 1122-7. PMID 24669015 DOI: 10.1093/annonc/mdu124 |
0.323 |
|
| 2014 |
Davies AH, Reipas KM, Pambid MR, Berns R, Stratford AL, Fotovati A, Firmino N, Astanehe A, Hu K, Maxwell C, Mills GB, Dunn SE. YB-1 transforms human mammary epithelial cells through chromatin remodeling leading to the development of basal-like breast cancer. Stem Cells (Dayton, Ohio). 32: 1437-50. PMID 24648416 DOI: 10.1002/stem.1707 |
0.303 |
|
| 2014 |
Meric-Bernstam F, Frampton GM, Ferrer-Lozano J, Yelensky R, Pérez-Fidalgo JA, Wang Y, Palmer GA, Ross JS, Miller VA, Su X, Eroles P, Barrera JA, Burgues O, Lluch AM, Zheng X, ... ... Mills GB, et al. Concordance of genomic alterations between primary and recurrent breast cancer. Molecular Cancer Therapeutics. 13: 1382-9. PMID 24608573 DOI: 10.1158/1535-7163.MCT-13-0482 |
0.372 |
|
| 2014 |
Bailey AM, Mao Y, Zeng J, Holla V, Johnson A, Brusco L, Chen K, Mendelsohn J, Routbort MJ, Mills GB, Meric-Bernstam F. Implementation of biomarker-driven cancer therapy: existing tools and remaining gaps. Discovery Medicine. 17: 101-14. PMID 24534473 |
0.308 |
|
| 2014 |
Werner HM, Mills GB, Ram PT. Cancer Systems Biology: a peek into the future of patient care? Nature Reviews. Clinical Oncology. 11: 167-76. PMID 24492837 DOI: 10.1038/nrclinonc.2014.6 |
0.309 |
|
| 2014 |
Cheng H, Liu P, Zhang F, Xu E, Symonds L, Ohlson CE, Bronson RT, Maira SM, Di Tomaso E, Li J, Myers AP, Cantley LC, Mills GB, Zhao JJ. A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition. Cancer Research. 74: 15-23. PMID 24322983 DOI: 10.1158/0008-5472.Can-13-0544 |
0.31 |
|
| 2014 |
Wolf J, Müller-Decker K, Flechtenmacher C, Zhang F, Shahmoradgoli M, Mills GB, Hoheisel JD, Boettcher M. An in vivo RNAi screen identifies SALL1 as a tumor suppressor in human breast cancer with a role in CDH1 regulation Oncogene. 33: 4273-4278. PMID 24292671 DOI: 10.1038/Onc.2013.515 |
0.383 |
|
| 2014 |
Lindholm EM, Krohn M, Iadevaia S, Kristian A, Mills GB, Mnl̃andsmo GM, Engebraaten O. Proteomic characterization of breast cancer xenografts identifies early and late bevacizumab-induced responses and predicts effective drug combinations Clinical Cancer Research. 20: 404-412. PMID 24192926 DOI: 10.1158/1078-0432.Ccr-13-1865 |
0.334 |
|
| 2014 |
Panupinthu N, Yu S, Zhang D, Zhang F, Gagea M, Lu Y, Grandis JR, Dunn SE, Lee HY, Mills GB. Self-reinforcing loop of amphiregulin and Y-box binding protein-1 contributes to poor outcomes in ovarian cancer. Oncogene. 33: 2846-56. PMID 23851501 DOI: 10.1038/Onc.2013.259 |
0.314 |
|
| 2014 |
Weinstein JN, Kim J, Creighton CJ, Akbani R, Hoadley KA, Kim WY, Morgan MB, Hinoue T, Rosenberg JE, Bajorin DF, Hansel DE, Al-Ahmadie H, Gordenin D, Stuart JM, Robertson G, ... ... Mills GB, et al. Comprehensive molecular profiling of urothelial bladder cancer at the DNA, RNA, and protein levels: A TCGA project. Journal of Clinical Oncology. 32: 4509-4509. DOI: 10.1200/Jco.2014.32.15_Suppl.4509 |
0.304 |
|
| 2014 |
Matulonis U, Wulf GM, Birrer MJ, Westin SN, Quy P, Bell-McGuinn KM, Lasonde B, Whalen C, Aghajanian C, Solit DB, Mills GB, Cantley L, Winer EP. Phase I study of oral BKM120 and oral olaparib for high-grade serous ovarian cancer (HGSC) or triple-negative breast cancer (TNBC). Journal of Clinical Oncology. 32: 2510-2510. DOI: 10.1200/Jco.2014.32.15_Suppl.2510 |
0.326 |
|
| 2014 |
Molina J, Morlacchi P, Silva L, Dennison J, Mills G. Extracellular lactate cooperates with limited glucose and glutamine to sustain breast cancer cell survival by providing ATP, NADPH, amino acids, and glutathione Cancer and Metabolism. 2: 49. DOI: 10.1186/2049-3002-2-S1-P49 |
0.315 |
|
| 2014 |
Weinstein JN, Kim J, Creighton CJ, Akbani R, Hoadley KA, Kim WY, Morgan MB, Hinoue T, Cherniack A, Su X, Mungall AJ, Ryan MC, Rosenberg JE, Bajorin DF, Czerniak B, ... ... Mills GB, et al. Abstract 987: Comprehensive characterization of urothelial bladder cancer: a TCGA Project update Cancer Research. 74: 987-987. DOI: 10.1158/1538-7445.Am2014-987 |
0.386 |
|
| 2014 |
Mazumdar T, Byers LA, Ng P, Mills GB, Peng S, Diao L, Fan Y, Stemke-Hale K, Heymach JV, Myers JN, Glisson BS, Johnson FM. Abstract 903: Evaluation of predictive biomarkers and resistance mechanisms of PI3K pathway inhibition in head and neck squamous cell carcinoma Cancer Research. 74: 903-903. DOI: 10.1158/1538-7445.Am2014-903 |
0.336 |
|
| 2014 |
Mazumdar A, Poage G, Hill J, Zhang Y, Tsimelzon A, Chang J, Mills G, Brown P. Abstract 5279: Induced expression of PPM1A in ER-negative breast cancer cells inhibits growth by suppressing cell cycle Cancer Research. 74: 5279-5279. DOI: 10.1158/1538-7445.Am2014-5279 |
0.377 |
|
| 2014 |
Chaluvally-Raghavan P, Zhang F, Liu W, Tyler M, Yu S, Pradeep S, Ram P, Lu Y, Sood A, Mills G. Abstract 4396: MicroRNA MIR551B amplified at 3q26.2 locus activate c-KIT expression and causes resistance to anoikis of ovarian cancer cells Cancer Research. 74: 4396-4396. DOI: 10.1158/1538-7445.Am2014-4396 |
0.317 |
|
| 2014 |
Chen T, Zhao H, Mao Y, Qi Y, Eterovic AK, Shaw KRM, Moulder SL, Davies MA, Degroot JF, Kopetz SE, Meric-Bernstam F, Mills GB, Chen K. Abstract 4275: Identifying cancer driver mutations in clinical sequencing data Cancer Research. 74: 4275-4275. DOI: 10.1158/1538-7445.Am2014-4275 |
0.335 |
|
| 2014 |
Batra N, Speers C, Uray I, Mazumdar A, Tsimelzon A, Hilsenbeck S, Mills G, Brown P. Abstract 3299: Maternal embryonic leucine zipper kinase is critical for the growth and migration of triple negative breast cancer cells Cancer Research. 74: 3299-3299. DOI: 10.1158/1538-7445.Am2014-3299 |
0.401 |
|
| 2014 |
Pande M, Bondy M, Do K, Sahin AA, Ying J, Mills GB, Thompson P, Brewster A. Abstract 3271: The association between germline genetic variants in the PI3K-AKT-mTOR pathway and breast cancer disease free survival Cancer Research. 74: 3271-3271. DOI: 10.1158/1538-7445.Am2014-3271 |
0.331 |
|
| 2014 |
McAuliffe PF, Akcakanat A, Evans K, Eterovic AK, Zhao H, Chen K, Sangai T, Chen H, Do K, Holder AM, Sharma C, Symmans WF, Gagea M, Naff KA, Sahin A, ... ... Mills GB, et al. Abstract 1186: Patient-derived breast cancer xenografts demonstrate molecular evolution in the phosphatidylinositol 3-kinase pathway upon engraftment Cancer Research. 74: 1186-1186. DOI: 10.1158/1538-7445.Am2014-1186 |
0.381 |
|
| 2013 |
Chavez-Macgregor M, Liu S, De Melo-Gagliato D, Chen H, Do KA, Pusztai L, Fraser Symmans W, Nair L, Hortobagyi GN, Mills GB, Meric-Bernstam F, Gonzalez-Angulo AM. Differences in gene and protein expression and the effects of race/ethnicity on breast cancer subtypes. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 23: 316-23. PMID 24296856 DOI: 10.1158/1055-9965.EPI-13-0929 |
0.315 |
|
| 2013 |
Dupuy F, Griss T, Blagih J, Bridon G, Avizonis D, Ling C, Dong Z, Siwak DR, Annis MG, Mills GB, Muller WJ, Siegel PM, Jones RG. LKB1 is a central regulator of tumor initiation and pro-growth metabolism in ErbB2-mediated breast cancer. Cancer & Metabolism. 1: 18. PMID 24280377 DOI: 10.1186/2049-3002-1-18 |
0.366 |
|
| 2013 |
Daemen A, Griffith OL, Heiser LM, Wang NJ, Enache OM, Sanborn Z, Pepin F, Durinck S, Korkola JE, Griffith M, Hur JS, Huh N, Chung J, Cope L, Fackler MJ, ... ... Mills GB, et al. Modeling precision treatment of breast cancer. Genome Biology. 14: R110. PMID 24176112 DOI: 10.1186/Gb-2013-14-10-R110 |
0.333 |
|
| 2013 |
Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, Beroukhim R, Bernard B, Wu CJ, Genovese G, Shmulevich I, ... ... Mills GB, et al. The somatic genomic landscape of glioblastoma. Cell. 155: 462-77. PMID 24120142 DOI: 10.1016/J.Cell.2013.09.034 |
0.318 |
|
| 2013 |
Li S, Shen D, Shao J, Crowder R, Liu W, Prat A, He X, Liu S, Hoog J, Lu C, Ding L, Griffith OL, Miller C, Larson D, Fulton RS, ... ... Mills GB, et al. Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Reports. 4: 1116-30. PMID 24055055 DOI: 10.1016/J.Celrep.2013.08.022 |
0.317 |
|
| 2013 |
Klempner SJ, Myers AP, Mills GB, Westin SN. Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer. Expert Opinion On Pharmacotherapy. 14: 2171-82. PMID 23937415 DOI: 10.1517/14656566.2013.826650 |
0.345 |
|
| 2013 |
Sohn J, Do KA, Liu S, Chen H, Mills GB, Hortobagyi GN, Meric-Bernstam F, Gonzalez-Angulo AM. Functional proteomics characterization of residual triple-negative breast cancer after standard neoadjuvant chemotherapy. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 24: 2522-6. PMID 23925999 DOI: 10.1093/annonc/mdt248 |
0.362 |
|
| 2013 |
Liang J, Mills GB. AMPK: a contextual oncogene or tumor suppressor? Cancer Research. 73: 2929-35. PMID 23644529 DOI: 10.1158/0008-5472.CAN-12-3876 |
0.332 |
|
| 2013 |
Tabchy A, Eltonsy N, Housman DE, Mills GB. Systematic identification of combinatorial drivers and targets in cancer cell lines. Plos One. 8: e60339. PMID 23577104 DOI: 10.1371/journal.pone.0060339 |
0.348 |
|
| 2013 |
Dutta P, Bui T, Bauckman KA, Keyomarsi K, Mills GB, Nanjundan M. EVI1 splice variants modulate functional responses in ovarian cancer cells. Molecular Oncology. 7: 647-68. PMID 23517670 DOI: 10.1016/J.Molonc.2013.02.008 |
0.333 |
|
| 2013 |
Sansores-Garcia L, Atkins M, Moya IM, Shahmoradgoli M, Tao C, Mills GB, Halder G. Mask is required for the activity of the Hippo pathway effector Yki/YAP. Current Biology : Cb. 23: 229-35. PMID 23333314 DOI: 10.1016/J.Cub.2012.12.033 |
0.327 |
|
| 2013 |
Hunt KK, Wingate H, Yokota T, Liu Y, Mills GB, Zhang F, Fang B, Su CH, Zhang M, Yi M, Keyomarsi K. Elafin, an inhibitor of elastase, is a prognostic indicator in breast cancer. Breast Cancer Research : Bcr. 15: R3. PMID 23320734 DOI: 10.1186/Bcr3374 |
0.362 |
|
| 2013 |
Holder AM, Gonzalez-Angulo AM, Chen H, Akcakanat A, Do KA, Fraser Symmans W, Pusztai L, Hortobagyi GN, Mills GB, Meric-Bernstam F. High stearoyl-CoA desaturase 1 expression is associated with shorter survival in breast cancer patients. Breast Cancer Research and Treatment. 137: 319-27. PMID 23208590 DOI: 10.1007/s10549-012-2354-4 |
0.38 |
|
| 2013 |
Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK, Nilsson MB, Gudikote J, Tran H, Cardnell RJ, Bearss DJ, ... ... Mills GB, et al. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 279-90. PMID 23091115 DOI: 10.1158/1078-0432.Ccr-12-1558 |
0.326 |
|
| 2013 |
Tabchy A, Eltonsy N, Housman DE, Mills GB. Correction: Systematic identification of combinatorial drivers and targets in cancer cell lines (PLoS ONE) Plos One. 8. DOI: 10.1371/annotation/85d86c29-4ba6-4bf0-94f6-2977b3e1c792 |
0.304 |
|
| 2013 |
Cardnell R, Diao L, Wang J, Bearss D, Warner S, Fan YH, Giri U, Story MD, Weinstein JN, Coombes KR, Williams MD, Genome Atlas Reseach Network TC, Wistuba II, Mills GB, Myers J, et al. An epithelial-mesenchymal transition (EMT) gene signature to predict resistance to EGFR inhibition and AXL identification as a therapeutic target in head and neck squamous cell carcinoma. Journal of Clinical Oncology. 31: 6011-6011. DOI: 10.1200/Jco.2013.31.15_Suppl.6011 |
0.38 |
|
| 2013 |
Dillon LM, Bean JR, Yang W, Balko JM, McDonald WH, Friedman DB, Gonzalez-Angulo AM, Mills GB, Arteaga CL, Miller TW. Abstract PR05: P-REX1 creates a positive feedback loop to activate growth factor receptor/PI3K signaling Molecular Cancer Research. 11. DOI: 10.1158/1557-3125.Advbc-Pr05 |
0.357 |
|
| 2013 |
Dillon LM, Bean JR, Balko JM, McDonald WH, Friedman DB, Gonzalez-Angulo AM, Mills GB, Arteaga CL, Miller TW. Abstract LB-37: P-REX1 is a novel PTEN-interacting protein that activates PI3K signaling in breast cancer. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Lb-37 |
0.359 |
|
| 2013 |
Ellis MJ, Li S, Shen D, Ding L, Crowder R, Shao J, Goncalves R, Tao Y, Luo J, Prat A, Liu W, Gonzalez-Angulo AM, Liu S, McMichael JF, Miller C, ... ... Mills GB, et al. Abstract LB-265: Patient-derived xenografts from advanced luminal-type breast cancer: insights into endocrine therapy resistance. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Lb-265 |
0.4 |
|
| 2013 |
Mazumdar A, Hollander PD, Poage G, Hill J, Zhang Y, Tsimelzon A, Hilsenbeck S, Chang J, Mills G, Brown PH. Abstract 856: High expression of DUSP4 in ER-negative breast cancer cells suppresses growth and invasion. Cancer Research. 73: 856-856. DOI: 10.1158/1538-7445.Am2013-856 |
0.358 |
|
| 2013 |
Lui VW, Allen EV, Li H, Zhang F, Zeng Y, Johnson JT, Garraway LA, Mills GB, Grandis JR. Abstract 4565: Whole exome sequencing links MAPK1 mutation to exquisite sensitivity to brief erlotinib monotherapy in head and neck cancer. Cancer Research. 73: 4565-4565. DOI: 10.1158/1538-7445.Am2013-4565 |
0.301 |
|
| 2013 |
Klempner SJ, Myers AP, Li J, Mills G, Cantley LC. Abstract 4265: Derivation and characterization of endometrial cancer cells resistant to phosphatidylinositol-3-kinase (PI3K) pathway inhibitors. Cancer Research. 73: 4265-4265. DOI: 10.1158/1538-7445.Am2013-4265 |
0.361 |
|
| 2013 |
Lui V, Peyser N, Ng PKS, Sen M, Li H, Zeng Y, Joyce S, Wang ZJ, Hammerman P, Mills G, Grandis JR. Abstract 4260: PTPRT mutation induces STAT3 activation in HNSCC preclinical models. Cancer Research. 73: 4260-4260. DOI: 10.1158/1538-7445.Am2013-4260 |
0.303 |
|
| 2013 |
Burstein MD, Tsimelzon A, Covington KR, Fuqua SA, Chang JC, Hilsenbeck SG, Osborne CK, Mills GB, Lau CC, Brown PH. Abstract 1996: Identification of four subgroups of Triple Negative Breast Cancer (TNBC) by genomic profiling. Cancer Research. 73: 1996-1996. DOI: 10.1158/1538-7445.Am2013-1996 |
0.342 |
|
| 2013 |
Labidi-Galy I, Clauss A, Ng V, Duraisamy S, Elias KM, Bilal E, Davidowitz RA, Lu Y, Badalian-Very G, Piao H, Kang U, Ficarro S, Ganesan S, Mills GB, Marto J, et al. Abstract B74: Elafin drives poor outcome in high-grade serous ovarian cancers and basal-like breast tumors Clinical Cancer Research. 19. DOI: 10.1158/1078-0432.Ovca13-B74 |
0.408 |
|
| 2013 |
Burstein, Tsimelzon A, Hilsenbeck S, Fuqua S, Chang J, Osborne C, Mills G, Brown P, Lau C. Abstract P4-06-01: Expression and DNA copy number profiling suggest novel therapeutic approaches for triple negative breast cancer subtypes Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-P4-06-01 |
0.304 |
|
| 2013 |
Matulonis U, Wulf G, Cantley L, Mills G, Lasonde B, Atkinson T, Whalen C, Isakoff S, Westin S, Bell-McGuinn K, Winer E. Abstract OT1-4-02: Phase I study of the combination of BKM120 and olaparib for the treatment of high grade serous ovarian cancer (HGSC) and triple negative breast cancer (TNBC) Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-Ot1-4-02 |
0.38 |
|
| 2012 |
Mitra S, Cheng KW, Mills GB. Rab25 in cancer: a brief update. Biochemical Society Transactions. 40: 1404-8. PMID 23176489 DOI: 10.1042/BST20120249 |
0.314 |
|
| 2012 |
Gonzalez-Angulo AM, Liu S, Chen H, Chavez-Macgregor M, Sahin A, Hortobagyi GN, Mills GB, Do KA, Meric-Bernstam F. Functional proteomics characterization of residual breast cancer after neoadjuvant systemic chemotherapy. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 24: 909-16. PMID 23139263 DOI: 10.1093/annonc/mds530 |
0.314 |
|
| 2012 |
Verhaak RG, Mills GB. Regulation of mRNA expression in breast cancer - a cis-tematic trans-action. Breast Cancer Research : Bcr. 14: 322. PMID 23106814 DOI: 10.1186/bcr3227 |
0.324 |
|
| 2012 |
Meric-Bernstam F, Chen H, Akcakanat A, Do KA, Lluch A, Hennessy BT, Hortobagyi GN, Mills GB, Gonzalez-Angulo A. Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer. Breast Cancer Research : Bcr. 14: R138. PMID 23102376 DOI: 10.1186/bcr3343 |
0.343 |
|
| 2012 |
Liang H, Cheung LW, Li J, Ju Z, Yu S, Stemke-Hale K, Dogruluk T, Lu Y, Liu X, Gu C, Guo W, Scherer SE, Carter H, Westin SN, Dyer MD, ... ... Mills GB, et al. Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. Genome Research. 22: 2120-9. PMID 23028188 DOI: 10.1101/Gr.137596.112 |
0.342 |
|
| 2012 |
Kamel D, Brady B, Tabchy A, Mills GB, Hennessy B. Proteomic classification of breast cancer Current Drug Targets. 13: 1495-1509. PMID 22974393 DOI: 10.2174/138945012803530080 |
0.319 |
|
| 2012 |
Byers LA, Wang J, Nilsson MB, Fujimoto J, Saintigny P, Yordy J, Giri U, Peyton M, Fan YH, Diao L, Masrorpour F, Shen L, Liu W, Duchemann B, Tumula P, ... ... Mills GB, et al. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discovery. 2: 798-811. PMID 22961666 DOI: 10.1158/2159-8290.Cd-12-0112 |
0.325 |
|
| 2012 |
Sangai T, Akcakanat A, Chen H, Tarco E, Wu Y, Do KA, Miller TW, Arteaga CL, Mills GB, Gonzalez-Angulo AM, Meric-Bernstam F. Biomarkers of response to Akt inhibitor MK-2206 in breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 5816-28. PMID 22932669 DOI: 10.1158/1078-0432.CCR-12-1141 |
0.343 |
|
| 2012 |
Simpkins F, Hevia-Paez P, Sun J, Ullmer W, Gilbert CA, da Silva T, Pedram A, Levin ER, Reis IM, Rabinovich B, Azzam D, Xu XX, Ince TA, Yang JY, Verhaak RG, ... ... Mills GB, et al. Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 5911-23. PMID 22896656 DOI: 10.1158/1078-0432.Ccr-12-1257 |
0.348 |
|
| 2012 |
Blumenschein GR, Mills GB, Gonzalez-Angulo AM. Targeting the hepatocyte growth factor-cMET axis in cancer therapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 3287-96. PMID 22869872 DOI: 10.1200/JCO.2011.40.3774 |
0.437 |
|
| 2012 |
Balko JM, Cook RS, Vaught DB, Kuba MG, Miller TW, Bhola NE, Sanders ME, Granja-Ingram NM, Smith JJ, Meszoely IM, Salter J, Dowsett M, Stemke-Hale K, González-Angulo AM, Mills GB, et al. Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. Nature Medicine. 18: 1052-9. PMID 22683778 DOI: 10.1038/Nm.2795 |
0.42 |
|
| 2012 |
Bast RC, Mills GB. Dissecting "PI3Kness": the complexity of personalized therapy for ovarian cancer. Cancer Discovery. 2: 16-8. PMID 22585163 DOI: 10.1158/2159-8290.Cd-11-0323 |
0.307 |
|
| 2012 |
Duong MT, Akli S, Wei C, Wingate HF, Liu W, Lu Y, Yi M, Mills GB, Hunt KK, Keyomarsi K. LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients. Plos Genetics. 8: e1002538. PMID 22479189 DOI: 10.1371/Journal.Pgen.1002538 |
0.358 |
|
| 2012 |
Horiuchi D, Kusdra L, Huskey NE, Chandriani S, Lenburg ME, Gonzalez-Angulo AM, Creasman KJ, Bazarov AV, Smyth JW, Davis SE, Yaswen P, Mills GB, Esserman LJ, Goga A. MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition. The Journal of Experimental Medicine. 209: 679-96. PMID 22430491 DOI: 10.1084/Jem.20111512 |
0.403 |
|
| 2012 |
Kim N, He N, Kim C, Zhang F, Lu Y, Yu Q, Stemke-Hale K, Greshock J, Wooster R, Yoon S, Mills GB. Systematic analysis of genotype-specific drug responses in cancer. International Journal of Cancer. 131: 2456-64. PMID 22422301 DOI: 10.1002/ijc.27529 |
0.318 |
|
| 2012 |
Muranen T, Selfors LM, Worster DT, Iwanicki MP, Song L, Morales FC, Gao S, Mills GB, Brugge JS. Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer Cell. 21: 227-39. PMID 22340595 DOI: 10.1016/J.Ccr.2011.12.024 |
0.365 |
|
| 2012 |
Mills GB. An emerging toolkit for targeted cancer therapies. Genome Research. 22: 177-82. PMID 22301131 DOI: 10.1101/gr.136044.111 |
0.301 |
|
| 2012 |
Astanehe A, Finkbeiner MR, Krzywinski M, Fotovati A, Dhillon J, Berquin IM, Mills GB, Marra MA, Dunn SE. MKNK1 is a YB-1 target gene responsible for imparting trastuzumab resistance and can be blocked by RSK inhibition. Oncogene. 31: 4434-46. PMID 22249268 DOI: 10.1038/Onc.2011.617 |
0.344 |
|
| 2012 |
Gonzalez-Angulo AM, Iwamoto T, Liu S, Chen H, Do KA, Hortobagyi GN, Mills GB, Meric-Bernstam F, Symmans WF, Pusztai L. Gene expression, molecular class changes, and pathway analysis after neoadjuvant systemic therapy for breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 1109-19. PMID 22235097 DOI: 10.1158/1078-0432.CCR-11-2762 |
0.319 |
|
| 2012 |
Li X, Lu Y, Liang K, Hsu JM, Albarracin C, Mills GB, Hung MC, Fan Z. Brk/PTK6 sustains activated EGFR signaling through inhibiting EGFR degradation and transactivating EGFR. Oncogene. 31: 4372-83. PMID 22231447 DOI: 10.1038/Onc.2011.608 |
0.361 |
|
| 2012 |
Park YY, Kim K, Kim SB, Hennessy BT, Kim SM, Park ES, Lim JY, Li J, Lu Y, Gonzalez-Angulo AM, Jeong W, Mills GB, Safe S, Lee JS. Reconstruction of nuclear receptor network reveals that NR2E3 is a novel upstream regulator of ESR1 in breast cancer. Embo Molecular Medicine. 4: 52-67. PMID 22174013 DOI: 10.1002/Emmm.201100187 |
0.365 |
|
| 2012 |
Mitra S, Stemke-Hale K, Mills GB, Claerhout S. Interactions between tumor cells and microenvironment in breast cancer: a new opportunity for targeted therapy. Cancer Science. 103: 400-7. PMID 22151725 DOI: 10.1111/j.1349-7006.2011.02183.x |
0.37 |
|
| 2012 |
Heiser LM, Sadanandam A, Kuo WL, Benz SC, Goldstein TC, Ng S, Gibb WJ, Wang NJ, Ziyad S, Tong F, Bayani N, Hu Z, Billig JI, Dueregger A, Lewis S, ... ... Mills GB, et al. Subtype and pathway specific responses to anticancer compounds in breast cancer. Proceedings of the National Academy of Sciences of the United States of America. 109: 2724-9. PMID 22003129 DOI: 10.1073/Pnas.1018854108 |
0.37 |
|
| 2012 |
Pradeep CR, Köstler WJ, Lauriola M, Granit RZ, Zhang F, Jacob-Hirsch J, Rechavi G, Nair HB, Hennessy BT, Gonzalez-Angulo AM, Tekmal RR, Ben-Porath I, Mills GB, Domany E, Yarden Y. Modeling ductal carcinoma in situ: a HER2-Notch3 collaboration enables luminal filling. Oncogene. 31: 907-17. PMID 21743488 DOI: 10.1038/Onc.2011.279 |
0.353 |
|
| 2012 |
Bast RC, Mills GB. Alterations in oncogenes, tumor suppressor genes, and growth factors associated with epithelial ovarian cancers. Methods in Molecular Medicine. 39: 37-48. PMID 21340756 DOI: 10.1385/1-59259-071-3:37 |
0.331 |
|
| 2012 |
Meric-Bernstam F, Frampton G, Ferrer-Lozano J, Yelensky R, Palmer GA, Cronin MT, Stephens PJ, Hale KS, Barrera J, Burgues O, Lluch A, Mills GB, Gonzalez-Angulo AM. Cancer gene profile of metastatic breast cancer. Journal of Clinical Oncology. 30: 1015-1015. DOI: 10.1200/JCO.2012.30.15_SUPPL.1015 |
0.359 |
|
| 2012 |
Brewster AM, Bondy M, Do K, Sahin A, Hale K, Wei C, Mills G, Thompson P. Abstract B84: The association between germline genetic variants in the PI3K pathway and PI3K mutations in breast tumors. Cancer Prevention Research. 5. DOI: 10.1158/1940-6207.Prev-12-B84 |
0.333 |
|
| 2012 |
Hartman ZC, Tsimelzon A, Uray IP, Hill J, Zhang Y, Mazumdar A, Hilsenbeck SG, Chang J, Mills GB, Brown PH. Abstract 4862: Autocrine secreted IL-6 and IL-8 play critical and non-redundant roles in basal-like breast cancer cell transformation and growthin vitroandin vivo Cancer Research. 72: 4862-4862. DOI: 10.1158/1538-7445.Am2012-4862 |
0.305 |
|
| 2012 |
Muranen TE, Selfors L, Worster D, Iwanicki M, Song L, Morlaes F, Mills GB, Brugge JS. Abstract 4836: Inhibition of PI3K/mTOR leads to adaptive resistance in extracellular matrix attached cancer cells Cancer Research. 72: 4836-4836. DOI: 10.1158/1538-7445.Am2012-4836 |
0.409 |
|
| 2012 |
Mazumdar A, Hollander PD, Tsimelzon A, Hilsenbeck S, Chang J, Mills G, Brown P. Abstract 2857: Induced expression of DUSP4 and PPM1A in ER-negative breast cancer cells suppresses proliferation and invasion Cancer Research. 72: 2857-2857. DOI: 10.1158/1538-7445.Am2012-2857 |
0.366 |
|
| 2012 |
Hollander Pd, Mazumdar A, Tsimelzon A, Hilsenbeck S, Chang J, Mills G, Brown P. Abstract 2853: Discovery of phosphatases that regulate growth and tumorigenicity of ER-negative breast cancers Cancer Research. 72: 2853-2853. DOI: 10.1158/1538-7445.Am2012-2853 |
0.368 |
|
| 2012 |
Fu X, Kumar V, Shea M, Biswal N, Nanda S, Chayanam S, Mitchell T, Hergenroeder G, Meerbrey K, Joshi A, Westbrook T, Mills G, Creighton C, Hilsenbeck S, Osborne C, et al. Abstract PD01-01: Overcoming endocrine therapy resistance related to PTEN loss by strategic combinations with mTOR, AKT, or MEK inhibitors Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-Pd01-01 |
0.355 |
|
| 2012 |
Chaluvally-Raghavan P, Zhang F, Pradeep S, Hee-Dong H, Lu Y, Borresen-Dale A, Flores E, Sood A, Mills G. Abstract P5-10-03: OncomiR-569 deregulate p53 pathway and initiate breast oncogenesis Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-P5-10-03 |
0.31 |
|
| 2012 |
Zoeller JJ, Bronson RT, Gilmer TM, Selfors LM, Lu Y, Mills GB, Brugge JS. Abstract P4-08-05: Basement membrane localized tumor cells are protected from HER2-targeted therapy in vivo. Cancer Research. 72: 4834-4834. DOI: 10.1158/0008-5472.Sabcs12-P4-08-05 |
0.313 |
|
| 2012 |
Horiuchi D, Kusdra L, Huskey NE, Chandriani S, Lenburg ME, Gonzalez-Angulo AM, Creasman KJ, Bazarov AV, Smyth JW, Davis SE, Yaswen P, Mills GB, Esserman LJ, Goga A. MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition The Journal of Cell Biology. 197: i1-i1. DOI: 10.1083/JCB1971OIA1 |
0.34 |
|
| 2011 |
Balko JM, Cook RS, Miller TW, Bhola NE, Sanders M, Granja-Ingram NM, Sanchez V, Meszoely IM, Salter J, Dowsett M, Stemke-Hale K, Gonzalez-Angulo AM, Mills GB, Arteaga CL. Use of gene expression patterns post neoadjuvant chemotherapy to identify a role for the MAPK phosphatase DUSP4 in therapeutic resistance and a stem-like phenotype in basal-like breast cancer (BLBC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 10509. PMID 28022377 DOI: 10.1200/Jco.2011.29.15_Suppl.10509 |
0.402 |
|
| 2011 |
Gonzalez-Angulo AM, Green MC, Murray JL, Palla SL, Koenig KH, Brewster AM, Valero V, Ibrahim NK, Moulder SL, Litton JK, Crawford DJ, Flores PR, Dryden MJ, Symmans WF, Giordano SH, ... ... Mills GB, et al. Open label, randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC (T-FEC) versus the combination of paclitaxel and RAD001 followed by FEC (TR-FEC) in women with triple receptor-negative breast cancer (TNBC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 1016. PMID 28020756 DOI: 10.1200/jco.2011.29.15_suppl.1016 |
0.409 |
|
| 2011 |
Chavez-MacGregor M, Liu S, Chen H, Do K, Pusztai L, Symmans WF, Hortobagyi GN, Mills GB, Meric-Bernstam F, Gonzalez-Angulo AM. Relationship between differences in RNA or protein expression and the effects of race/ethnicity on breast cancer outcomes. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 157. PMID 27957979 DOI: 10.1200/jco.2011.29.27_suppl.157 |
0.336 |
|
| 2011 |
Lee JS, Kim JH, Park YY, Mills GB. Systems biology approaches to decoding the genome of liver cancer. Cancer Research and Treatment : Official Journal of Korean Cancer Association. 43: 205-11. PMID 22247704 DOI: 10.4143/crt.2011.43.4.205 |
0.389 |
|
| 2011 |
Miller TW, Balko JM, Fox EM, Ghazoui Z, Dunbier A, Anderson H, Dowsett M, Jiang A, Adam Smith R, Maira SM, Charles Manning H, González-Angulo AM, Mills GB, Higham C, Chanthaphaychith S, et al. ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer Cancer Discovery. 1: 338-351. PMID 22049316 DOI: 10.1158/2159-8290.Cd-11-0101 |
0.364 |
|
| 2011 |
Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR, Romero IL, Carey MS, Mills GB, Hotamisligil GS, Yamada SD, Peter ME, Gwin K, Lengyel E. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nature Medicine. 17: 1498-503. PMID 22037646 DOI: 10.1038/Nm.2492 |
0.305 |
|
| 2011 |
Fox EM, Miller TW, Balko JM, Kuba MG, Sánchez V, Smith RA, Liu S, González-Angulo AM, Mills GB, Ye F, Shyr Y, Manning HC, Buck E, Arteaga CL. A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer. Cancer Research. 71: 6773-84. PMID 21908557 DOI: 10.1158/0008-5472.Can-11-1295 |
0.357 |
|
| 2011 |
Gonzalez-Angulo AM, Hennessy BT, Meric-Bernstam F, Sahin A, Liu W, Ju Z, Carey MS, Myhre S, Speers C, Deng L, Broaddus R, Lluch A, Aparicio S, Brown P, Pusztai L, ... ... Mills GB, et al. Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer. Clinical Proteomics. 8: 11. PMID 21906370 DOI: 10.1186/1559-0275-8-11 |
0.318 |
|
| 2011 |
Hu R, Peng G, Dai H, Breuer EK, Stemke-Hale K, Li K, Gonzalez-Angulo AM, Mills GB, Lin SY. ZNF668 functions as a tumor suppressor by regulating p53 stability and function in breast cancer. Cancer Research. 71: 6524-34. PMID 21852383 DOI: 10.1158/0008-5472.CAN-11-0853 |
0.324 |
|
| 2011 |
Liu P, Cheng H, Santiago S, Raeder M, Zhang F, Isabella A, Yang J, Semaan DJ, Chen C, Fox EA, Gray NS, Monahan J, Schlegel R, Beroukhim R, Mills GB, et al. Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms. Nature Medicine. 17: 1116-20. PMID 21822287 DOI: 10.1038/Nm.2402 |
0.376 |
|
| 2011 |
Stronach EA, Alfraidi A, Rama N, Datler C, Studd JB, Agarwal R, Guney TG, Gourley C, Hennessy BT, Mills GB, Mai A, Brown R, Dina R, Gabra H. HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer Cancer Research. 71: 4412-4422. PMID 21571862 DOI: 10.1158/0008-5472.CAN-10-4111 |
0.323 |
|
| 2011 |
Rexer BN, Ham AJ, Rinehart C, Hill S, Granja-Ingram Nde M, González-Angulo AM, Mills GB, Dave B, Chang JC, Liebler DC, Arteaga CL. Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition. Oncogene. 30: 4163-74. PMID 21499296 DOI: 10.1038/Onc.2011.130 |
0.377 |
|
| 2011 |
Tabchy A, Hennessy BT, Gonzalez-Angulo AM, Bernstam FM, Lu Y, Mills GB. Quantitative proteomic analysis in breast cancer. Drugs of Today (Barcelona, Spain : 1998). 47: 169-82. PMID 21431104 DOI: 10.1358/dot.2011.47.2.1576695 |
0.336 |
|
| 2011 |
Kim SJ, Kim JS, Park ES, Lee JS, Lin Q, Langley RR, Maya M, He J, Kim SW, Weihua Z, Balasubramanian K, Fan D, Mills GB, Hung MC, Fidler IJ. Astrocytes upregulate survival genes in tumor cells and induce protection from chemotherapy. Neoplasia (New York, N.Y.). 13: 286-98. PMID 21390191 DOI: 10.1593/Neo.11112 |
0.32 |
|
| 2011 |
Miller TW, Balko JM, Ghazoui Z, Dunbier A, Anderson H, Dowsett M, González-Angulo AM, Mills GB, Miller WR, Wu H, Shyr Y, Arteaga CL. A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance Clinical Cancer Research. 17: 2024-2034. PMID 21346144 DOI: 10.1158/1078-0432.Ccr-10-2567 |
0.409 |
|
| 2011 |
Ghosh R, Narasanna A, Wang SE, Liu S, Chakrabarty A, Balko JM, González-Angulo AM, Mills GB, Penuel E, Winslow J, Sperinde J, Dua R, Pidaparthi S, Mukherjee A, Leitzel K, et al. Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers. Cancer Research. 71: 1871-82. PMID 21324925 DOI: 10.1158/0008-5472.Can-10-1872 |
0.393 |
|
| 2011 |
Zhu QS, Rosenblatt K, Huang KL, Lahat G, Brobey R, Bolshakov S, Nguyen T, Ding Z, Belousov R, Bill K, Luo X, Lazar A, Dicker A, Mills GB, Hung MC, et al. Vimentin is a novel AKT1 target mediating motility and invasion. Oncogene. 30: 457-70. PMID 20856200 DOI: 10.1038/Onc.2010.421 |
0.326 |
|
| 2011 |
Agarwal R, Carey M, Hennessy B, Mills GB. PI3K pathway-directed therapeutic strategies in cancer. Current Opinion in Investigational Drugs (London, England : 2000). 11: 615-28. PMID 20496256 |
0.307 |
|
| 2011 |
Irwin ME, Nelson L, Santiago-O'Farrill JM, Miller CP, Siwak DR, Mills GB, Li S, Hughes DP, Chandra J. Small Molecule Inhibitors of HER2 Inhibit Proliferative Signaling and Promote Apoptosis in Ph+ ALL Blood. 118: 1397-1397. DOI: 10.1182/BLOOD.V118.21.1397.1397 |
0.318 |
|
| 2011 |
Hartman ZC, Tsimelzon A, Hill J, Zhang Y, Mazumdar A, Hilsenbeck SG, Mills G, Brown PH. Abstract A42: Autocrine-produced IL-6 and IL-8 are essential for the growth and maintenance of the transformed phenotype of basal-like breast cancer cells Cancer Prevention Research. 4. DOI: 10.1158/1940-6207.Prev-11-A42 |
0.358 |
|
| 2011 |
Mao M, Tsao L, Dayyani F, Nanda VGY, Mills G, Bollag G, Davies M, Gallick G, Kopetz S. Abstract LB-228: Resistance to BRAF inhibition in BRAF V600E colorectal cancer is associated with PI3K/AKT activation and hypermethylation Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-228 |
0.356 |
|
| 2011 |
Joy AM, Smirnov I, Ramesh A, Kim S, Bachoo R, Sarkaria J, Ram P, Shapiro W, Mills G, Feuerstein B. Abstract 4138: Five prognostic subgroups differ in expression of Akt pathway genes: Biomarkers for therapy selection Cancer Research. 71: 4138-4138. DOI: 10.1158/1538-7445.Am2011-4138 |
0.313 |
|
| 2011 |
Park Y, Kim K, Kim S, Hennessy B, Kim SM, Park ES, Lim JY, Li J, Lu Y, Gonzalez-Angulo A, Mills G, Safe S, Lee J. Abstract 356: Reconstruction of nuclear receptor network reveals that NR2E3 is a novel upstream regulator of ESR1 in breast cancer Cancer Research. 71: 356-356. DOI: 10.1158/1538-7445.Am2011-356 |
0.372 |
|
| 2011 |
Muranen TE, Morales F, Selfors L, Worster D, Albeck J, Gao S, Iwanicki M, Mills G, Brugge JS. Abstract 1540: Targeting PI3K/mTOR inhibitor induced survival programs abrogates resistance to cell death in ECM-attached cancer cells Cancer Research. 71: 1540-1540. DOI: 10.1158/1538-7445.Am2011-1540 |
0.446 |
|
| 2011 |
Dennison JB, Molina JR, Guo H, Mills GB. Abstract 1273: Metabolic networks and the role of LDHB in breast cancer Cancer Research. 71: 1273-1273. DOI: 10.1158/1538-7445.Am2011-1273 |
0.337 |
|
| 2011 |
Boudreau A, Yau C, Petrillo L, Stemke-Hale K, Mills G, Gray J, Wolf D, Veer Lv‘. P5-01-05: Activating Mutations in PIK3CA or AKT1 in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657). Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P5-01-05 |
0.307 |
|
| 2011 |
Molina J, Dennison J, Zhang F, Mills G. P4-05-03: Mechanism Underlying Metabolic Heterogeneity in Breast Cancer Subtypes. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P4-05-03 |
0.325 |
|
| 2011 |
Pradeep C, Koestler W, Lauriola M, Nair H, Rao R, Mills G, Yarden Y. P2-03-04: Novel Pathways Underlying the Initiation and Transition of DCIS to IDC of HER2−Overexpressing Breast Cancer Model. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P2-03-04 |
0.37 |
|
| 2011 |
Brugge J, Muranen T, Zoeller J, Worster D, Iwanicki M, Selfors L, Mills G. DL1-1: Adaptive Resistance to Targeted Therapies. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-Dl1-1 |
0.319 |
|
| 2011 |
McAuliffe PF, Gonzalez-Angulo A, Akcakanat A, Chen H, Hale KS, Do K, Sharma C, Symmans WF, Mills GB, Meric-Bernstam F. Characterization of patient-derived breast cancer xenografts demonstrates molecular evolution Journal of the American College of Surgeons. 213: S28. DOI: 10.1016/J.JAMCOLLSURG.2011.06.049 |
0.311 |
|
| 2010 |
McAuliffe PF, Meric-Bernstam F, Mills GB, Gonzalez-Angulo AM. Deciphering the role of PI3K/Akt/mTOR pathway in breast cancer biology and pathogenesis. Clinical Breast Cancer. 10: S59-65. PMID 21115423 DOI: 10.3816/CBC.2010.s.013 |
0.367 |
|
| 2010 |
Liang K, Esteva FJ, Albarracin C, Stemke-Hale K, Lu Y, Bianchini G, Yang CY, Li Y, Li X, Chen CT, Mills GB, Hortobagyi GN, Mendelsohn J, Hung MC, Fan Z. Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation. Cancer Cell. 18: 423-35. PMID 21075308 DOI: 10.1016/j.ccr.2010.10.025 |
0.384 |
|
| 2010 |
Luyimbazi D, Akcakanat A, McAuliffe PF, Zhang L, Singh G, Gonzalez-Angulo AM, Chen H, Do KA, Zheng Y, Hung MC, Mills GB, Meric-Bernstam F. Rapamycin regulates stearoyl CoA desaturase 1 expression in breast cancer. Molecular Cancer Therapeutics. 9: 2770-84. PMID 20876744 DOI: 10.1158/1535-7163.MCT-09-0980 |
0.39 |
|
| 2010 |
Irie HY, Shrestha Y, Selfors LM, Frye F, Iida N, Wang Z, Zou L, Yao J, Lu Y, Epstein CB, Natesan S, Richardson AL, Polyak K, Mills GB, Hahn WC, et al. PTK6 regulates IGF-1-induced anchorage-independent survival. Plos One. 5: e11729. PMID 20668531 DOI: 10.1371/Journal.Pone.0011729 |
0.365 |
|
| 2010 |
Cai D, Shames DS, Raso MG, Xie Y, Kim YH, Pollack JR, Girard L, Sullivan JP, Gao B, Peyton M, Nanjundan M, Byers L, Heymach J, Mills G, Gazdar AF, et al. Steroid receptor coactivator-3 expression in lung cancer and its role in the regulation of cancer cell survival and proliferation. Cancer Research. 70: 6477-85. PMID 20663904 DOI: 10.1158/0008-5472.Can-10-0005 |
0.345 |
|
| 2010 |
Iadevaia S, Lu Y, Morales FC, Mills GB, Ram PT. Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis. Cancer Research. 70: 6704-14. PMID 20643779 DOI: 10.1158/0008-5472.Can-10-0460 |
0.324 |
|
| 2010 |
Creighton CJ, Fu X, Hennessy BT, Casa AJ, Zhang Y, Gonzalez-Angulo AM, Lluch A, Gray JW, Brown PH, Hilsenbeck SG, Osborne CK, Mills GB, Lee AV, Schiff R. Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. Breast Cancer Research : Bcr. 12: R40. PMID 20569503 DOI: 10.1186/Bcr2594 |
0.332 |
|
| 2010 |
Bast RC, Mills GB. Personalizing therapy for ovarian cancer: BRCAness and beyond. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 3545-8. PMID 20547987 DOI: 10.1200/Jco.2010.28.5791 |
0.366 |
|
| 2010 |
Miller TW, Hennessy BT, González-Angulo AM, Fox EM, Mills GB, Chen H, Higham C, García-Echeverría C, Shyr Y, Arteaga CL. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. The Journal of Clinical Investigation. 120: 2406-13. PMID 20530877 DOI: 10.1172/Jci41680 |
0.436 |
|
| 2010 |
Altman MK, Gopal V, Jia W, Yu S, Hall H, Mills GB, McGinnis AC, Bartlett MG, Jiang G, Madan D, Prestwich GD, Xu Y, Davies MA, Murph MM. Targeting melanoma growth and viability reveals dualistic functionality of the phosphonothionate analogue of carba cyclic phosphatidic acid. Molecular Cancer. 9: 140. PMID 20529378 DOI: 10.1186/1476-4598-9-140 |
0.307 |
|
| 2010 |
Yang G, Rosen DG, Liu G, Yang F, Guo X, Xiao X, Xue F, Mercado-Uribe I, Huang J, Lin SH, Mills GB, Liu J. CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 3875-86. PMID 20505188 DOI: 10.1158/1078-0432.CCR-10-0483 |
0.309 |
|
| 2010 |
Yang G, Chang B, Yang F, Guo X, Cai KQ, Xiao XS, Wang H, Sen S, Hung MC, Mills GB, Chang S, Multani AS, Mercado-Uribe I, Liu J. Aurora kinase A promotes ovarian tumorigenesis through dysregulation of the cell cycle and suppression of BRCA2. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 3171-81. PMID 20423983 DOI: 10.1158/1078-0432.Ccr-09-3171 |
0.359 |
|
| 2010 |
Lu ZH, Shvartsman MB, Lee AY, Shao JM, Murray MM, Kladney RD, Fan D, Krajewski S, Chiang GG, Mills GB, Arbeit JM. Mammalian target of rapamycin activator RHEB is frequently overexpressed in human carcinomas and is critical and sufficient for skin epithelial carcinogenesis. Cancer Research. 70: 3287-98. PMID 20388784 DOI: 10.1158/0008-5472.Can-09-3467 |
0.334 |
|
| 2010 |
Pontier SM, Huck L, White DE, Rayment J, Sanguin-Gendreau V, Hennessy B, Zuo D, St-Arnaud R, Mills GB, Dedhar S, Marshall CJ, Muller WJ. Integrin-linked kinase has a critical role in ErbB2 mammary tumor progression: Implications for human breast cancer Oncogene. 29: 3374-3385. PMID 20305688 DOI: 10.1038/Onc.2010.86 |
0.33 |
|
| 2010 |
Panupinthu N, Lee HY, Mills GB. Lysophosphatidic acid production and action: critical new players in breast cancer initiation and progression. British Journal of Cancer. 102: 941-6. PMID 20234370 DOI: 10.1038/sj.bjc.6605588 |
0.368 |
|
| 2010 |
Mills GB, Yarden Y. The rebirth of a phoenix: ovarian cancers are addicted to ErbB-3. Cancer Cell. 17: 217-8. PMID 20227035 DOI: 10.1016/J.Ccr.2010.02.023 |
0.333 |
|
| 2010 |
Park ES, Rabinovsky R, Carey M, Hennessy BT, Agarwal R, Liu W, Ju Z, Deng W, Lu Y, Woo HG, Kim SB, Cheong JH, Garraway LA, Weinstein JN, Mills GB, et al. Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set. Molecular Cancer Therapeutics. 9: 257-67. PMID 20124458 DOI: 10.1158/1535-7163.Mct-09-0743 |
0.314 |
|
| 2010 |
Siwak DR, Carey M, Hennessy BT, Nguyen CT, McGahren Murray MJ, Nolden L, Mills GB. Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges. Journal of Oncology. 2010: 568938. PMID 20037743 DOI: 10.1155/2010/568938 |
0.36 |
|
| 2010 |
Murray JL, Thompson P, Tuna M, Brewster AM, Do K, Edgerton ME, Sahin A, Mills GB, Tsachavidis S, Bondy M. Association of gene copy number alterations in formalin-fixed, paraffin-embedded tumors with prognostic molecular and pathologic tumor subtypes in early-stage breast cancer. Journal of Clinical Oncology. 28: 572-572. DOI: 10.1200/Jco.2010.28.15_Suppl.572 |
0.332 |
|
| 2010 |
Thompson P, Do K, Brewster AM, Shim J, Murray JL, Tsachavidis S, Sahin A, Mills GB, Bondy M. Integration of specific copy number imbalances and prediction models of early-stage breast cancer recurrence. Journal of Clinical Oncology. 28: 1529-1529. DOI: 10.1200/Jco.2010.28.15_Suppl.1529 |
0.318 |
|
| 2010 |
Jiralerspong S, Liu S, Palla SL, Mills GB, Hung M, Hortobagyi GN, Gonzalez-Angulo AM. Correlation of Snail expression and survival in patients with early-stage triple-negative breast cancer (TNBC). Journal of Clinical Oncology. 28: 10525-10525. DOI: 10.1200/Jco.2010.28.15_Suppl.10525 |
0.34 |
|
| 2010 |
Morales FC, Iadevaia S, Lu Y, Ram P, Mills GB. Phosphoproteomics and mass-action modeling to predict optimal drug combination in signaling networks Clinical Cancer Research. 16. DOI: 10.1158/Diag-10-B32 |
0.341 |
|
| 2010 |
Goga A, Horiuchi D, Kusdra L, Chandriani S, Lenburg M, Gonzalez-Angulo A, Huskey N, Creasman K, Davis S, Mills G, Esserman L. Abstract S5-4: Synthetic-Lethality of Triple-Negative Breast Cancers Via the MYC Oncogene Pathway Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-S5-4 |
0.416 |
|
| 2009 |
Mills GB, Jurisica I, Yarden Y, Norman JC. Genomic amplicons target vesicle recycling in breast cancer. The Journal of Clinical Investigation. 119: 2123-7. PMID 19620778 DOI: 10.1172/Jci40256 |
0.382 |
|
| 2009 |
Li TT, Alemayehu M, Aziziyeh AI, Pape C, Pampillo M, Postovit LM, Mills GB, Babwah AV, Bhattacharya M. Beta-arrestin/Ral signaling regulates lysophosphatidic acid-mediated migration and invasion of human breast tumor cells. Molecular Cancer Research : McR. 7: 1064-77. PMID 19609003 DOI: 10.1158/1541-7786.Mcr-08-0578 |
0.317 |
|
| 2009 |
Maurer M, Su T, Saal LH, Koujak S, Hopkins BD, Barkley CR, Wu J, Nandula S, Dutta B, Xie Y, Chin YR, Kim DI, Ferris JS, Gruvberger-Saal SK, Laakso M, ... ... Mills GB, et al. 3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma. Cancer Research. 69: 6299-306. PMID 19602588 DOI: 10.1158/0008-5472.Can-09-0820 |
0.365 |
|
| 2009 |
Vasudevan KM, Barbie DA, Davies MA, Rabinovsky R, McNear CJ, Kim JJ, Hennessy BT, Tseng H, Pochanard P, Kim SY, Dunn IF, Schinzel AC, Sandy P, Hoersch S, Sheng Q, ... ... Mills GB, et al. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell. 16: 21-32. PMID 19573809 DOI: 10.1016/J.Ccr.2009.04.012 |
0.35 |
|
| 2009 |
Agarwal R, Gonzalez-Angulo AM, Myhre S, Carey M, Lee JS, Overgaard J, Alsner J, Stemke-Hale K, Lluch A, Neve RM, Kuo WL, Sorlie T, Sahin A, Valero V, Keyomarsi K, ... ... Mills GB, et al. Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 3654-62. PMID 19470724 DOI: 10.1158/1078-0432.Ccr-08-3293 |
0.303 |
|
| 2009 |
Chen Y, Guggisberg N, Jorda M, Gonzalez-Angulo A, Hennessy B, Mills GB, Tan CK, Slingerland JM. Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 3396-405. PMID 19451593 DOI: 10.1158/1078-0432.Ccr-08-3127 |
0.357 |
|
| 2009 |
Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, Gilcrease MZ, Krishnamurthy S, Lee JS, Fridlyand J, Sahin A, Agarwal R, Joy C, Liu W, Stivers D, Baggerly K, Carey M, Lluch A, ... ... Mills GB, et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Research. 69: 4116-24. PMID 19435916 DOI: 10.1158/0008-5472.Can-08-3441 |
0.389 |
|
| 2009 |
Miller TW, Pérez-Torres M, Narasanna A, Guix M, Stål O, Pérez-Tenorio G, Gonzalez-Angulo AM, Hennessy BT, Mills GB, Kennedy JP, Lindsley CW, Arteaga CL. Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer. Cancer Research. 69: 4192-201. PMID 19435893 DOI: 10.1158/0008-5472.Can-09-0042 |
0.352 |
|
| 2009 |
Zou CY, Smith KD, Zhu QS, Liu J, McCutcheon IE, Slopis JM, Meric-Bernstam F, Peng Z, Bornmann WG, Mills GB, Lazar AJ, Pollock RE, Lev D. Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor. Molecular Cancer Therapeutics. 8: 1157-68. PMID 19417153 DOI: 10.1158/1535-7163.Mct-08-1008 |
0.336 |
|
| 2009 |
Yim EK, Peng G, Dai H, Hu R, Li K, Lu Y, Mills GB, Meric-Bernstam F, Hennessy BT, Craven RJ, Lin SY. Rak functions as a tumor suppressor by regulating PTEN protein stability and function. Cancer Cell. 15: 304-14. PMID 19345329 DOI: 10.1016/j.ccr.2009.02.012 |
0.344 |
|
| 2009 |
Nikolova DA, Asangani IA, Nelson LD, Hughes DP, Siwak DR, Mills GB, Harms A, Buchholz E, Pilz LR, Manegold C, Allgayer H. Cetuximab attenuates metastasis and u-PAR expression in non-small cell lung cancer: u-PAR and E-cadherin are novel biomarkers of cetuximab sensitivity. Cancer Research. 69: 2461-70. PMID 19276367 DOI: 10.1158/0008-5472.CAN-08-3236 |
0.312 |
|
| 2009 |
Gonzalez-Angulo AM, Stemke-Hale K, Palla SL, Carey M, Agarwal R, Meric-Berstam F, Traina TA, Hudis C, Hortobagyi GN, Gerald WL, Mills GB, Hennessy BT. Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 2472-8. PMID 19276248 DOI: 10.1158/1078-0432.CCR-08-1763 |
0.312 |
|
| 2009 |
Hennessy BT, Gonzalez-Angulo AM, Carey MS, Mills GB. A systems approach to analysis of molecular complexity in breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 417-9. PMID 19147744 DOI: 10.1158/1078-0432.CCR-08-2620 |
0.341 |
|
| 2009 |
Mirzoeva OK, Das D, Heiser LM, Bhattacharya S, Siwak D, Gendelman R, Bayani N, Wang NJ, Neve RM, Guan Y, Hu Z, Knight Z, Feiler HS, Gascard P, Parvin B, ... ... Mills GB, et al. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Research. 69: 565-72. PMID 19147570 DOI: 10.1158/0008-5472.Can-08-3389 |
0.397 |
|
| 2009 |
Ghosh R, Narasanna A, Gonazalez-Angulo A, Mills G, Arteaga C. Differential Signaling by ErbB Receptor (HER) Dimers: Implications for Response to Anti-HER2 Therapies in Breast Cancer. Cancer Research. 69: 705-705. DOI: 10.1158/0008-5472.Sabcs-09-705 |
0.342 |
|
| 2009 |
Creighton C, Fu X, Hilsenbeck S, Osborne C, Hennessy B, Mills G, Lee A, Schiff R. Gene Expression Signatures of PI3K Signaling Are Associated with Low ER Levels and the Luminal B Subtype in Breast Cancer Cell Lines and Human Tumors, and in Patients Predicts Poor Outcome. Cancer Research. 69: 31-31. DOI: 10.1158/0008-5472.Sabcs-09-31 |
0.341 |
|
| 2009 |
Berns K, Horlings H, Halfwerk J, Hennessy B, Linn S, Hauptmann M, Mills G, van de Vijver M, Bernards R. 57 A functional genetic approach identifies the PI3K pathway as a major determinant of Trastuzumab resistance in breast cancer European Journal of Cancer Supplements. 7: 17. DOI: 10.1016/S1359-6349(09)70060-6 |
0.323 |
|
| 2008 |
Gonzalez-Angulo AM, Hennessy BT, Ju Z, Meric-Bernstam F, Lajos P, Symmans WF, Coombes KR, Hortobagyi GN, Mills GB. Functional proteomic-based predictor of pathologic complete response to neoadjuvant chemotherapy with paclitaxel/FAC-FEC in breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 11078. PMID 27947715 DOI: 10.1200/jco.2008.26.15_suppl.11078 |
0.318 |
|
| 2008 |
Kim WY, Chang DJ, Hennessy B, Kang HJ, Yoo J, Han SH, Kim YS, Park HJ, Seo SY, Geo SY, Mills G, Kim KW, Hong WK, Suh YG, Lee HY. A novel derivative of the natural agent deguelin for cancer chemoprevention and therapy. Cancer Prevention Research (Philadelphia, Pa.). 1: 577-87. PMID 19139008 DOI: 10.1158/1940-6207.CAPR-08-0184 |
0.325 |
|
| 2008 |
Lu Z, Luo RZ, Lu Y, Zhang X, Yu Q, Khare S, Kondo S, Kondo Y, Yu Y, Mills GB, Liao WS, Bast RC. The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. The Journal of Clinical Investigation. 118: 3917-29. PMID 19033662 DOI: 10.1172/Jci35512 |
0.337 |
|
| 2008 |
Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, Carey M, Hu Z, Guan Y, Sahin A, Symmans WF, Pusztai L, Nolden LK, Horlings H, Berns K, ... ... Mills GB, et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Research. 68: 6084-91. PMID 18676830 DOI: 10.1158/0008-5472.CAN-07-6854 |
0.358 |
|
| 2008 |
Hennessy BT, Murph M, Nanjundan M, Carey M, Auersperg N, Almeida J, Coombes KR, Liu J, Lu Y, Gray JW, Mills GB. Ovarian cancer: linking genomics to new target discovery and molecular markers--the way ahead. Advances in Experimental Medicine and Biology. 617: 23-40. PMID 18497028 DOI: 10.1007/978-0-387-69080-3_3 |
0.389 |
|
| 2008 |
Shafee N, Smith CR, Wei S, Kim Y, Mills GB, Hortobagyi GN, Stanbridge EJ, Lee EY. Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. Cancer Research. 68: 3243-50. PMID 18451150 DOI: 10.1158/0008-5472.Can-07-5480 |
0.313 |
|
| 2008 |
Zhu QS, Ren W, Korchin B, Lahat G, Dicker A, Lu Y, Mills G, Pollock RE, Lev D. Soft tissue sarcoma cells are highly sensitive to AKT blockade: A role for p53-independent up-regulation of GADD45α Cancer Research. 68: 2895-2903. PMID 18413758 DOI: 10.1158/0008-5472.CAN-07-6268 |
0.331 |
|
| 2008 |
Wei Y, Xia W, Zhang Z, Liu J, Wang H, Adsay NV, Albarracin C, Yu D, Abbruzzese JL, Mills GB, Bast RC, Hortobagyi GN, Hung MC. Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Molecular Carcinogenesis. 47: 701-6. PMID 18176935 DOI: 10.1002/Mc.20413 |
0.308 |
|
| 2008 |
Ashworth A, Balkwill F, Bast RC, Berek JS, Kaye A, Boyd JA, Mills G, Weinstein JN, Woolley K, Workman P. Opportunities and challenges in ovarian cancer research, a perspective from the 11th Ovarian cancer action/HHMT Forum, Lake Como, March 2007. Gynecologic Oncology. 108: 652-7. PMID 18096210 DOI: 10.1016/J.Ygyno.2007.11.014 |
0.332 |
|
| 2007 |
Hennessy BT, Lu Y, Poradosu E, Yu Q, Yu S, Hall H, Carey MS, Ravoori M, Gonzalez-Angulo AM, Birch R, Henderson IC, Kundra V, Mills GB. Pharmacodynamic markers of perifosine efficacy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 7421-31. PMID 18094426 DOI: 10.1158/1078-0432.CCR-07-0760 |
0.37 |
|
| 2007 |
Murph M, Tanaka T, Pang J, Felix E, Liu S, Trost R, Godwin AK, Newman R, Mills G. Liquid Chromatography Mass Spectrometry for Quantifying Plasma Lysophospholipids: Potential Biomarkers for Cancer Diagnosis Methods in Enzymology. 433: 1-25. PMID 17954226 DOI: 10.1016/S0076-6879(07)33001-2 |
0.328 |
|
| 2007 |
Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, Beijersbergen RL, Mills GB, van de Vijver MJ, Bernards R. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell. 12: 395-402. PMID 17936563 DOI: 10.1016/j.ccr.2007.08.030 |
0.406 |
|
| 2007 |
Lu CH, Wyszomierski SL, Tseng LM, Sun MH, Lan KH, Neal CL, Mills GB, Hortobagyi GN, Esteva FJ, Yu D. Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 5883-8. PMID 17908983 DOI: 10.1158/1078-0432.Ccr-06-2837 |
0.351 |
|
| 2007 |
Guan Y, Kuo WL, Stilwell JL, Takano H, Lapuk AV, Fridlyand J, Mao JH, Yu M, Miller MA, Santos JL, Kalloger SE, Carlson JW, Ginzinger DG, Celniker SE, Mills GB, et al. Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 5745-55. PMID 17908964 DOI: 10.1158/1078-0432.Ccr-06-2882 |
0.336 |
|
| 2007 |
Lu Y, Li X, Liang K, Luwor R, Siddik ZH, Mills GB, Mendelsohn J, Fan Z. Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab. Cancer Research. 67: 8240-7. PMID 17804738 DOI: 10.1158/0008-5472.CAN-07-0589 |
0.304 |
|
| 2007 |
Yamasaki F, Johansen MJ, Zhang D, Krishnamurthy S, Felix E, Bartholomeusz C, Aguilar RJ, Kurisu K, Mills GB, Hortobagyi GN, Ueno NT. Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt. Cancer Research. 67: 5779-88. PMID 17575145 DOI: 10.1158/0008-5472.Can-06-3020 |
0.326 |
|
| 2007 |
Zhang Q, Bhola NE, Lui VW, Siwak DR, Thomas SM, Gubish CT, Siegfried JM, Mills GB, Shin D, Grandis JR. Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer. Molecular Cancer Therapeutics. 6: 1414-24. PMID 17431120 DOI: 10.1158/1535-7163.Mct-06-0678 |
0.333 |
|
| 2007 |
Murph M, Tanaka T, Liu S, Mills GB. Of spiders and crabs: the emergence of lysophospholipids and their metabolic pathways as targets for therapy in cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 6598-602. PMID 17121877 DOI: 10.1158/1078-0432.CCR-06-1721 |
0.332 |
|
| 2007 |
Davies M, Hennessy B, Mills GB. Point mutations of protein kinases and individualised cancer therapy. Expert Opinion On Pharmacotherapy. 7: 2243-61. PMID 17059381 DOI: 10.1517/14656566.7.16.2243 |
0.367 |
|
| 2007 |
Gonzalez-Angulo AM, Hennessy BT, Meric-Bernstam F, Lu Y, Symmans WF, Hortobagyi GN, Mills GB. Activation of the PI3K/AKT signal transduction pathway is inversely associated with estrogen receptor levels and correlates with survival in hormone receptor-positive Her2/neu-negative breast cancer Journal of Clinical Oncology. 25: 10588-10588. DOI: 10.1200/JCO.2007.25.18_SUPPL.10588 |
0.386 |
|
| 2006 |
Acconcia F, Manavathi B, Mascarenhas J, Talukder AH, Mills G, Kumar R. An inherent role of integrin-linked kinase-estrogen receptor alpha interaction in cell migration. Cancer Research. 66: 11030-8. PMID 17108142 DOI: 10.1158/0008-5472.CAN-06-2676 |
0.336 |
|
| 2006 |
Ping B, He X, Xia W, Lee DF, Wei Y, Yu D, Mills G, Shi D, Hung MC. Cytoplasmic expression of p21CIP1/WAF1 is correlated with IKKbeta overexpression in human breast cancers. International Journal of Oncology. 29: 1103-10. PMID 17016640 |
0.32 |
|
| 2006 |
Iwamaru A, Kondo Y, Iwado E, Aoki H, Fujiwara K, Yokoyama T, Mills GB, Kondo S. Silencing mammalian target of rapamycin signaling by small interfering RNA enhances rapamycin-induced autophagy in malignant glioma cells. Oncogene. 26: 1840-51. PMID 17001313 DOI: 10.1038/sj.onc.1209992 |
0.323 |
|
| 2006 |
Liang K, Lu Y, Li X, Zeng X, Glazer RI, Mills GB, Fan Z. Differential roles of phosphoinositide-dependent protein kinase-1 and akt1 expression and phosphorylation in breast cancer cell resistance to Paclitaxel, Doxorubicin, and gemcitabine. Molecular Pharmacology. 70: 1045-52. PMID 16782806 DOI: 10.1124/Mol.106.023333 |
0.421 |
|
| 2006 |
Koul D, Shen R, Bergh S, Sheng X, Shishodia S, Lafortune TA, Lu Y, de Groot JF, Mills GB, Yung WK. Inhibition of Akt survival pathway by a small-molecule inhibitor in human glioblastoma. Molecular Cancer Therapeutics. 5: 637-44. PMID 16546978 DOI: 10.1158/1535-7163.MCT-05-0453 |
0.318 |
|
| 2006 |
Cheng KW, Lu Y, Mills GB. Assay of Rab25 function in ovarian and breast cancers. Methods in Enzymology. 403: 202-15. PMID 16473588 DOI: 10.1016/S0076-6879(05)03017-X |
0.333 |
|
| 2006 |
Mandal M, Younes M, Swan EA, Jasser SA, Doan D, Yigitbasi O, McMurphey A, Ludwick J, El-Naggar AK, Bucana C, Mills GB, Myers JN. The Akt inhibitor KP372-1 inhibits proliferation and induces apoptosis and anoikis in squamous cell carcinoma of the head and neck. Oral Oncology. 42: 430-9. PMID 16442835 DOI: 10.1016/j.oraloncology.2005.09.011 |
0.308 |
|
| 2006 |
Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nature Reviews. Drug Discovery. 4: 988-1004. PMID 16341064 DOI: 10.1038/nrd1902 |
0.357 |
|
| 2005 |
Huang G, Krig S, Kowbel D, Xu H, Hyun B, Volik S, Feuerstein B, Mills GB, Stokoe D, Yaswen P, Collins C. ZNF217 suppresses cell death associated with chemotherapy and telomere dysfunction. Human Molecular Genetics. 14: 3219-25. PMID 16203743 DOI: 10.1093/HMG/DDI352 |
0.339 |
|
| 2005 |
Eder AM, Sui X, Rosen DG, Nolden LK, Cheng KW, Lahad JP, Kango-Singh M, Lu KH, Warneke CL, Atkinson EN, Bedrosian I, Keyomarsi K, Kuo WL, Gray JW, Yin JC, ... ... Mills GB, et al. Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America. 102: 12519-24. PMID 16116079 DOI: 10.1073/Pnas.0505641102 |
0.308 |
|
| 2005 |
Younes MN, Kim S, Yigitbasi OG, Mandal M, Jasser SA, Dakak Yazici Y, Schiff BA, El-Naggar A, Bekele BN, Mills GB, Myers JN. Integrin-linked kinase is a potential therapeutic target for anaplastic thyroid cancer. Molecular Cancer Therapeutics. 4: 1146-56. PMID 16093430 DOI: 10.1158/1535-7163.MCT-05-0078 |
0.354 |
|
| 2005 |
Nishimoto A, Yu Y, Lu Z, Mao X, Ren Z, Watowich SS, Mills GB, Liao WS, Chen X, Bast RC, Luo RZ. A Ras homologue member I directly inhibits signal transducers and activators of transcription 3 translocation and activity in human breast and ovarian cancer cells. Cancer Research. 65: 6701-10. PMID 16061651 DOI: 10.1158/0008-5472.Can-05-0130 |
0.317 |
|
| 2005 |
Mandal M, Kim S, Younes MN, Jasser SA, El-Naggar AK, Mills GB, Myers JN. The Akt inhibitor KP372-1 suppresses Akt activity and cell proliferation and induces apoptosis in thyroid cancer cells. British Journal of Cancer. 92: 1899-905. PMID 15870708 DOI: 10.1038/sj.bjc.6602595 |
0.334 |
|
| 2005 |
Cheng KW, Lahad JP, Gray JW, Mills GB. Emerging role of RAB GTPases in cancer and human disease. Cancer Research. 65: 2516-9. PMID 15805241 DOI: 10.1158/0008-5472.CAN-05-0573 |
0.336 |
|
| 2005 |
Meric-Bernstam F, Mills GB. Mammalian target of rapamycin. Seminars in Oncology. 31: 10-7; discussion 33. PMID 15799239 DOI: 10.1053/J.SEMINONCOL.2004.10.013 |
0.416 |
|
| 2005 |
Mondesire WH, Jian W, Zhang H, Ensor J, Hung MC, Mills GB, Meric-Bernstam F. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 7031-42. PMID 15501983 DOI: 10.1158/1078-0432.CCR-04-0361 |
0.403 |
|
| 2004 |
Cheng KW, Lahad JP, Kuo WL, Lapuk A, Yamada K, Auersperg N, Liu J, Smith-McCune K, Lu KH, Fishman D, Gray JW, Mills GB. The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nature Medicine. 10: 1251-6. PMID 15502842 DOI: 10.1038/nm1125 |
0.39 |
|
| 2004 |
Umezu-Goto M, Tanyi J, Lahad J, Liu S, Yu S, Lapushin R, Hasegawa Y, Lu Y, Trost R, Bevers T, Jonasch E, Aldape K, Liu J, James RD, Ferguson CG, ... ... Mills GB, et al. Lysophosphatidic acid production and action: validated targets in cancer? Journal of Cellular Biochemistry. 92: 1115-40. PMID 15258897 DOI: 10.1002/Jcb.20113 |
0.321 |
|
| 2004 |
Cheng KW, Lahad JP, Mills GB. Analysis of molecular aberrations in ovarian cancer allows novel target identification. Journal of Obstetrics and Gynaecology Canada : Jogc = Journal D'Obstetrique Et Gynecologie Du Canada : Jogc. 26: 461-74. PMID 15151733 DOI: 10.1016/S1701-2163(16)30657-0 |
0.317 |
|
| 2004 |
Sellappan S, Grijalva R, Zhou X, Yang W, Eli MB, Mills GB, Yu D. Lineage infidelity of MDA-MB-435 cells: expression of melanocyte proteins in a breast cancer cell line. Cancer Research. 64: 3479-85. PMID 15150101 DOI: 10.1158/0008-5472.Can-3299-2 |
0.321 |
|
| 2004 |
Noh WC, Mondesire WH, Peng J, Jian W, Zhang H, Dong J, Mills GB, Hung MC, Meric-Bernstam F. Determinants of rapamycin sensitivity in breast cancer cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 1013-23. PMID 14871980 DOI: 10.1158/1078-0432.CCR-03-0043 |
0.349 |
|
| 2004 |
Lu Y, Wang H, Mills GB. Targeting PI3K-AKT pathway for cancer therapy. Reviews in Clinical and Experimental Hematology. 7: 205-28. PMID 14763163 |
0.385 |
|
| 2004 |
Lu Y, Luwor R, Liang K, Li X, Mills G, Mendelsohn J, Fan Z. 638 Acquired resistance to EGF receptor-targeted cancer therapy European Journal of Cancer Supplements. 2: 192-193. DOI: 10.1016/S1359-6349(04)80646-3 |
0.33 |
|
| 2003 |
Mills GB, Kohn E, Lu Y, Eder A, Fang X, Wang H, Bast RC, Gray J, Jaffe R, Hortobagyi G. Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer. Seminars in Oncology. 30: 93-104. PMID 14613030 DOI: 10.1053/J.Seminoncol.2003.08.011 |
0.444 |
|
| 2003 |
Hu SX, Wang S, Wang JP, Mills GB, Zhou Y, Xu HJ. Expression of endogenous granzyme B in a subset of human primary breast carcinomas. British Journal of Cancer. 89: 135-9. PMID 12838314 DOI: 10.1038/sj.bjc.6601051 |
0.331 |
|
| 2003 |
Knuefermann C, Lu Y, Liu B, Jin W, Liang K, Wu L, Schmidt M, Mills GB, Mendelsohn J, Fan Z. HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene. 22: 3205-12. PMID 12761490 DOI: 10.1038/sj.onc.1206394 |
0.407 |
|
| 2003 |
Liang K, Jin W, Knuefermann C, Schmidt M, Mills GB, Ang KK, Milas L, Fan Z. Targeting the phosphatidylinositol 3-kinase/Akt pathway for enhancing breast cancer cells to radiotherapy. Molecular Cancer Therapeutics. 2: 353-60. PMID 12700279 |
0.341 |
|
| 2003 |
Tanyi JL, Morris AJ, Wolf JK, Fang X, Hasegawa Y, Lapushin R, Auersperg N, Sigal YJ, Newman RA, Felix EA, Atkinson EN, Mills GB. The human lipid phosphate phosphatase-3 decreases the growth, survival, and tumorigenesis of ovarian cancer cells: validation of the lysophosphatidic acid signaling cascade as a target for therapy in ovarian cancer. Cancer Research. 63: 1073-82. PMID 12615725 |
0.35 |
|
| 2003 |
Cui X, Zhang P, Deng W, Oesterreich S, Lu Y, Mills GB, Lee AV. Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer. Molecular Endocrinology (Baltimore, Md.). 17: 575-88. PMID 12554765 DOI: 10.1210/me.2002-0318 |
0.367 |
|
| 2002 |
Fang X, Schummer M, Mao M, Yu S, Tabassam FH, Swaby R, Hasegawa Y, Tanyi JL, LaPushin R, Eder A, Jaffe R, Erickson J, Mills GB. Lysophosphatidic acid is a bioactive mediator in ovarian cancer. Biochimica Et Biophysica Acta. 1582: 257-64. PMID 12069836 DOI: 10.1016/S1388-1981(02)00179-8 |
0.312 |
|
| 2002 |
Hu L, Hofmann J, Lu Y, Mills GB, Jaffe RB. Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Research. 62: 1087-92. PMID 11861387 |
0.352 |
|
| 2002 |
Mills GB, Eder A, Fang X, Hasegawa Y, Mao M, Lu Y, Tanyi J, Tabassam FH, Wiener J, Lapushin R, Yu S, Parrott JA, Compton T, Tribley W, Fishman D, et al. Critical role of lysophospholipids in the pathophysiology, diagnosis, and management of ovarian cancer. Cancer Treatment and Research. 107: 259-83. PMID 11775454 |
0.321 |
|
| 2001 |
Mills GB, Lu Y, Fang X, Wang H, Eder A, Mao M, Swaby R, Cheng KW, Stokoe D, Siminovitch K, Jaffe R, Gray J. The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy. Seminars in Oncology. 28: 125-41. PMID 11706404 DOI: 10.1016/S0093-7754(01)90290-8 |
0.4 |
|
| 2000 |
Fang X, Gaudette D, Furui T, Mao M, Estrella V, Eder A, Pustilnik T, Sasagawa T, Lapushin R, Yu S, Jaffe RB, Wiener JR, Erickson JR, Mills GB. Lysophospholipid growth factors in the initiation, progression, metastases, and management of ovarian cancer. Annals of the New York Academy of Sciences. 905: 188-208. PMID 10818454 DOI: 10.1111/j.1749-6632.2000.tb06550.x |
0.331 |
|
| 1999 |
Lu Y, Lin YZ, LaPushin R, Cuevas B, Fang X, Yu SX, Davies MA, Khan H, Furui T, Mao M, Zinner R, Hung MC, Steck P, Siminovitch K, Mills GB. The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells. Oncogene. 18: 7034-45. PMID 10597304 DOI: 10.1038/Sj.Onc.1203183 |
0.338 |
|
| 1999 |
Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C, Pinkel D, Powell B, Mills GB, Gray JW. PIK3CA is implicated as an oncogene in ovarian cancer. Nature Genetics. 21: 99-102. PMID 9916799 DOI: 10.1038/5042 |
0.313 |
|
| 1999 |
Yu Y, Xu F, Peng H, Fang X, Zhao S, Li Y, Cuevas B, Kuo WL, Gray JW, Siciliano M, Mills GB, Bast RC. NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. Proceedings of the National Academy of Sciences of the United States of America. 96: 214-9. PMID 9874798 DOI: 10.1073/Pnas.96.1.214 |
0.346 |
|
| Show low-probability matches. |